WO2011069294A1 - N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 - Google Patents
N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 Download PDFInfo
- Publication number
- WO2011069294A1 WO2011069294A1 PCT/CN2009/075478 CN2009075478W WO2011069294A1 WO 2011069294 A1 WO2011069294 A1 WO 2011069294A1 CN 2009075478 W CN2009075478 W CN 2009075478W WO 2011069294 A1 WO2011069294 A1 WO 2011069294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- unsubstituted
- adenosine
- alkyl
- Prior art date
Links
- -1 N6-substituted adenosine Chemical class 0.000 title claims abstract description 1204
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 280
- 230000000147 hypnotic effect Effects 0.000 claims abstract description 13
- 239000000932 sedative agent Substances 0.000 claims abstract description 12
- 230000001624 sedative effect Effects 0.000 claims abstract description 12
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010012289 Dementia Diseases 0.000 claims abstract description 9
- 230000000648 anti-parkinson Effects 0.000 claims abstract description 9
- 239000000939 antiparkinson agent Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 202
- 229910052736 halogen Inorganic materials 0.000 claims description 193
- 150000002367 halogens Chemical class 0.000 claims description 189
- 229910052739 hydrogen Inorganic materials 0.000 claims description 178
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 172
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 171
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 149
- 229960005305 adenosine Drugs 0.000 claims description 149
- 125000003545 alkoxy group Chemical group 0.000 claims description 147
- 125000001424 substituent group Chemical group 0.000 claims description 126
- 125000002252 acyl group Chemical group 0.000 claims description 120
- 239000001257 hydrogen Substances 0.000 claims description 115
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 101
- 150000002431 hydrogen Chemical group 0.000 claims description 87
- 238000002360 preparation method Methods 0.000 claims description 84
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 78
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 78
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 78
- 125000004414 alkyl thio group Chemical group 0.000 claims description 74
- 125000004423 acyloxy group Chemical group 0.000 claims description 70
- 239000000460 chlorine Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 48
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 44
- 229910052801 chlorine Inorganic materials 0.000 claims description 37
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 30
- 125000001624 naphthyl group Chemical group 0.000 claims description 29
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 26
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 26
- 125000000539 amino acid group Chemical group 0.000 claims description 23
- 125000002541 furyl group Chemical group 0.000 claims description 23
- 125000001544 thienyl group Chemical group 0.000 claims description 23
- 125000002883 imidazolyl group Chemical group 0.000 claims description 22
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 22
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 19
- 125000001931 aliphatic group Chemical group 0.000 claims description 17
- 239000001961 anticonvulsive agent Substances 0.000 claims description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 17
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 claims description 10
- 229960003965 antiepileptics Drugs 0.000 claims description 10
- 150000002460 imidazoles Chemical class 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 9
- 230000001773 anti-convulsant effect Effects 0.000 claims description 9
- 230000003556 anti-epileptic effect Effects 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- 239000004305 biphenyl Substances 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- UGVIXKXYLBAZND-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(4-hydroxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(O)=CC=3)=C2N=C1 UGVIXKXYLBAZND-LSCFUAHRSA-N 0.000 claims description 5
- RRRLUFHDFDNPMZ-BPAMBQHCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-phenylpropyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RRRLUFHDFDNPMZ-BPAMBQHCSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- MRPKNNSABYPGBF-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-(benzylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC=CC=3)=C2N=C1 MRPKNNSABYPGBF-LSCFUAHRSA-N 0.000 claims description 4
- VOSIFZUHQCWGLR-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[(4-hydroxy-3-methoxyphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(O)C(OC)=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 VOSIFZUHQCWGLR-SCFUHWHPSA-N 0.000 claims description 4
- CKFQUSCIRFVDNO-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[6-[2-(3-hydroxy-4-methoxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(O)C(OC)=CC=C1CCNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 CKFQUSCIRFVDNO-NVQRDWNXSA-N 0.000 claims description 4
- RRRLUFHDFDNPMZ-BYMDKACISA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1r)-1-phenylpropyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RRRLUFHDFDNPMZ-BYMDKACISA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- RZVWFSHUCDKBDW-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-(1,3-benzodioxol-5-ylmethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=C4OCOC4=CC=3)=C2N=C1 RZVWFSHUCDKBDW-SCFUHWHPSA-N 0.000 claims description 3
- HKUVZSKOMPUWSJ-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(3,4-dihydroxyphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=C(O)C(O)=CC=3)=C2N=C1 HKUVZSKOMPUWSJ-LSCFUAHRSA-N 0.000 claims description 3
- AMUNEPVACAQVCN-SDBHATRESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(thiophen-3-ylmethylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC3=CSC=C3)=C2N=C1 AMUNEPVACAQVCN-SDBHATRESA-N 0.000 claims description 3
- ZWLZHFQBXQMCTK-DPHITLOKSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1r)-1-phenylethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZWLZHFQBXQMCTK-DPHITLOKSA-N 0.000 claims description 3
- ZWLZHFQBXQMCTK-QHOAOGIMSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-phenylethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZWLZHFQBXQMCTK-QHOAOGIMSA-N 0.000 claims description 3
- SGEXQCXUFHPEJQ-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[4-(trifluoromethyl)phenyl]methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(=CC=3)C(F)(F)F)=C2N=C1 SGEXQCXUFHPEJQ-LSCFUAHRSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229940070765 laurate Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 125000005257 alkyl acyl group Chemical group 0.000 claims 11
- 125000001041 indolyl group Chemical group 0.000 claims 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 8
- 229910052794 bromium Inorganic materials 0.000 claims 8
- SMBZJSVIKJMSFP-UHFFFAOYSA-N trifluoromethyl hypofluorite Chemical compound FOC(F)(F)F SMBZJSVIKJMSFP-UHFFFAOYSA-N 0.000 claims 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 5
- 150000002475 indoles Chemical class 0.000 claims 5
- BYVPAZHQSBQHQZ-TVEGRQPNSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[1-(3,4,5-trimethoxyphenyl)ethylamino]purin-9-yl]oxolane-3,4-diol Chemical compound COC1=C(OC)C(OC)=CC(C(C)NC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 BYVPAZHQSBQHQZ-TVEGRQPNSA-N 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 3
- CAGLGYNQQSIUGX-SDBHATRESA-N (2R,3R,4S,5R)-2-[6-(2-furanylmethylamino)-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3OC=CC=3)=C2N=C1 CAGLGYNQQSIUGX-SDBHATRESA-N 0.000 claims 2
- TVCZMUZIGULVHF-AJKMGBEJSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(1S)-2-hydroxy-1-phenylethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound OC[C@H](C1=CC=CC=C1)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=2N=CN=1 TVCZMUZIGULVHF-AJKMGBEJSA-N 0.000 claims 2
- CCBDZINEVBVRPC-UGTJMOTHSA-N (2r,3r,4s,5r)-2-[6-(9h-fluoren-9-ylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3C4=CC=CC=C4C4=CC=CC=C43)=C2N=C1 CCBDZINEVBVRPC-UGTJMOTHSA-N 0.000 claims 2
- STBHGUDBFRVICM-UGTJMOTHSA-N (2r,3r,4s,5r)-2-[6-(benzhydrylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 STBHGUDBFRVICM-UGTJMOTHSA-N 0.000 claims 2
- SZBULDQSDUXAPJ-XNIJJKJLSA-N (2r,3r,4s,5r)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCCC3)=C2N=C1 SZBULDQSDUXAPJ-XNIJJKJLSA-N 0.000 claims 2
- UUIOJKJCNRYLSX-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[6-[(3,4-dimethoxyphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(OC)C(OC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UUIOJKJCNRYLSX-NVQRDWNXSA-N 0.000 claims 2
- NTBGVBQLCFELBY-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(3-aminophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound NC1=CC=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 NTBGVBQLCFELBY-LSCFUAHRSA-N 0.000 claims 2
- TYVREJOFWWAYFY-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[(3-hydroxy-4-methoxyphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(O)C(OC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 TYVREJOFWWAYFY-SCFUHWHPSA-N 0.000 claims 2
- PMUVNAUPWLXPSA-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-aminophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC(N)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PMUVNAUPWLXPSA-LSCFUAHRSA-N 0.000 claims 2
- AVHZIEZVLFUQFK-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-chlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(Cl)=CC=3)=C2N=C1 AVHZIEZVLFUQFK-LSCFUAHRSA-N 0.000 claims 2
- VTIXNKKIYJGASE-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-fluorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(F)=CC=3)=C2N=C1 VTIXNKKIYJGASE-LSCFUAHRSA-N 0.000 claims 2
- WDPQHNDJXZITPS-BGIGGGFGSA-N (2r,3r,4s,5r)-2-[6-[(4-hydroxy-3,5-dimethoxyphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=C(O)C(OC)=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 WDPQHNDJXZITPS-BGIGGGFGSA-N 0.000 claims 2
- GOAKLLIBRAYJOI-ZKFWECIDSA-N (2r,3r,4s,5r)-2-[6-[1-(3,4-dimethoxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(OC)C(OC)=CC=C1C(C)NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 GOAKLLIBRAYJOI-ZKFWECIDSA-N 0.000 claims 2
- OBXFMRBCKJRJAD-XZNUSECASA-N (2r,3r,4s,5r)-2-[6-[1-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(N)C=CC=1C(C)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OBXFMRBCKJRJAD-XZNUSECASA-N 0.000 claims 2
- LJSCNWRFGRIEQT-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[2-(3,4-dihydroxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCCC=3C=C(O)C(O)=CC=3)=C2N=C1 LJSCNWRFGRIEQT-SCFUHWHPSA-N 0.000 claims 2
- XIYHDKXKWDQFSV-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[6-[2-(4-hydroxy-3-methoxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=C(O)C(OC)=CC(CCNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 XIYHDKXKWDQFSV-NVQRDWNXSA-N 0.000 claims 2
- DHMFJBXEQGOXHR-IUAXGMLLSA-N (2r,3r,4s,5r)-2-[6-[[(1r)-1-(4-chlorophenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N([C@H](C)C=1C=CC(Cl)=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DHMFJBXEQGOXHR-IUAXGMLLSA-N 0.000 claims 2
- RLDZWMWSRPIZLQ-IUAXGMLLSA-N (2r,3r,4s,5r)-2-[6-[[(1r)-1-(4-fluorophenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RLDZWMWSRPIZLQ-IUAXGMLLSA-N 0.000 claims 2
- RLDZWMWSRPIZLQ-YBGGAFRISA-N (2r,3r,4s,5r)-2-[6-[[(1s)-1-(4-fluorophenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RLDZWMWSRPIZLQ-YBGGAFRISA-N 0.000 claims 2
- NDKWIXMUYBMNPV-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[6-[benzyl(2-hydroxyethyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1N(CCO)CC1=CC=CC=C1 NDKWIXMUYBMNPV-NVQRDWNXSA-N 0.000 claims 2
- QQVDYAJHWNCBLK-NVQRDWNXSA-N (2r,3r,4s,5r)-2-[6-[benzyl(ethyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1N(CC)CC1=CC=CC=C1 QQVDYAJHWNCBLK-NVQRDWNXSA-N 0.000 claims 2
- VGSGPQLKDKJSOZ-SCFUHWHPSA-N (2r,3r,4s,5r)-2-[6-[benzyl(methyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1N(C)CC1=CC=CC=C1 VGSGPQLKDKJSOZ-SCFUHWHPSA-N 0.000 claims 2
- JPDSVXMTESDQEK-FDEMZPBOSA-N (2r,3r,4s,5r)-2-[6-[bis(2-hydroxypropyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N(CC(C)O)CC(O)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JPDSVXMTESDQEK-FDEMZPBOSA-N 0.000 claims 2
- GLPIVDGRYPPAMJ-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[cyclohexyl(methyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1N(C)C1CCCCC1 GLPIVDGRYPPAMJ-LSCFUAHRSA-N 0.000 claims 2
- SHBIQOVGLUASKT-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[6-[ethyl(2-hydroxyethyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N(CCO)CC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SHBIQOVGLUASKT-IDTAVKCVSA-N 0.000 claims 2
- BDBYTVQXDMOPHD-UEXBNONGSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(1-phenylbutylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=CC=CC=1C(CCC)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BDBYTVQXDMOPHD-UEXBNONGSA-N 0.000 claims 2
- ZWLZHFQBXQMCTK-BTBIENRZSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(1-phenylethylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=CC=CC=1C(C)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZWLZHFQBXQMCTK-BTBIENRZSA-N 0.000 claims 2
- RRRLUFHDFDNPMZ-XTMLTMLVSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(1-phenylpropylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=CC=CC=1C(CC)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RRRLUFHDFDNPMZ-XTMLTMLVSA-N 0.000 claims 2
- HWGBXKPHIGGCNS-IDTAVKCVSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(2-methylpropylamino)purin-9-yl]oxolane-3,4-diol Chemical compound C1=NC=2C(NCC(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HWGBXKPHIGGCNS-IDTAVKCVSA-N 0.000 claims 2
- NXSATUYYWOSHKH-SDBHATRESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(thiophen-2-ylmethylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3SC=CC=3)=C2N=C1 NXSATUYYWOSHKH-SDBHATRESA-N 0.000 claims 2
- HPIOHZNDWHIMOJ-KHTYJDQRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(3,4,5-trimethoxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound COC1=C(OC)C(OC)=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 HPIOHZNDWHIMOJ-KHTYJDQRSA-N 0.000 claims 2
- WBJVJFOITZTVRG-SCFUHWHPSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(3-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound CC1=CC=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 WBJVJFOITZTVRG-SCFUHWHPSA-N 0.000 claims 2
- VAQMNFPQRLLRMG-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 VAQMNFPQRLLRMG-LSCFUAHRSA-N 0.000 claims 2
- NIILKQXUUNHDMM-XNIJJKJLSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(5-methylfuran-2-yl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O1C(C)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIILKQXUUNHDMM-XNIJJKJLSA-N 0.000 claims 2
- GEYPSUBAIFHQJP-XNIJJKJLSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(5-methylthiophen-2-yl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound S1C(C)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 GEYPSUBAIFHQJP-XNIJJKJLSA-N 0.000 claims 2
- JNQOFFHRIGZTFB-XZNUSECASA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[1-(4-hydroxyphenyl)ethylamino]purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=C(O)C=CC=1C(C)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JNQOFFHRIGZTFB-XZNUSECASA-N 0.000 claims 2
- NCXWNNXFMOAYNB-XTMLTMLVSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[1-(4-hydroxyphenyl)propylamino]purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=C(O)C=CC=1C(CC)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NCXWNNXFMOAYNB-XTMLTMLVSA-N 0.000 claims 2
- IFMBILYAQMAGKX-JTXMXDKBSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[1-(4-methoxyphenyl)ethylamino]purin-9-yl]oxolane-3,4-diol Chemical compound C1=CC(OC)=CC=C1C(C)NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IFMBILYAQMAGKX-JTXMXDKBSA-N 0.000 claims 2
- DVYHPLRPSFNTOS-UEXBNONGSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[1-(4-methoxyphenyl)propylamino]purin-9-yl]oxolane-3,4-diol Chemical compound C=1C=C(OC)C=CC=1C(CC)NC(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DVYHPLRPSFNTOS-UEXBNONGSA-N 0.000 claims 2
- FSHTYAMZKGATIU-SDBHATRESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[2-(1h-imidazol-5-yl)ethylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCCC=3NC=NC=3)=C2N=C1 FSHTYAMZKGATIU-SDBHATRESA-N 0.000 claims 2
- QGCNEMXXKWZPHR-WVSUBDOOSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[2-(1h-indol-3-yl)ethylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCCC=3C4=CC=CC=C4NC=3)=C2N=C1 QGCNEMXXKWZPHR-WVSUBDOOSA-N 0.000 claims 2
- WOGMPRPPPAAONC-VONAAWGESA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1r)-1-(3-methoxyphenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound COC1=CC=CC([C@@H](C)NC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 WOGMPRPPPAAONC-VONAAWGESA-N 0.000 claims 2
- XFLWADPQOMQHRL-SSFGXONLSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1r)-1-(4-methylphenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@H](C)C=1C=CC(C)=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XFLWADPQOMQHRL-SSFGXONLSA-N 0.000 claims 2
- WOGMPRPPPAAONC-OJMQJXDZSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-(3-methoxyphenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound COC1=CC=CC([C@H](C)NC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 WOGMPRPPPAAONC-OJMQJXDZSA-N 0.000 claims 2
- IFMBILYAQMAGKX-OJMQJXDZSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-(4-methoxyphenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IFMBILYAQMAGKX-OJMQJXDZSA-N 0.000 claims 2
- XFLWADPQOMQHRL-KFAHYOAQSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-(4-methylphenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XFLWADPQOMQHRL-KFAHYOAQSA-N 0.000 claims 2
- KIJIEMNWSXTTSP-YBGGAFRISA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1s)-1-(4-nitrophenyl)ethyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KIJIEMNWSXTTSP-YBGGAFRISA-N 0.000 claims 2
- CCYLRAYLVGARQT-BFHYXJOUSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-[(2-hydroxyphenyl)methylamino]purin-9-yl]oxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=CC=3)O)=C2N=C1 CCYLRAYLVGARQT-BFHYXJOUSA-N 0.000 claims 2
- HDYYTVPJWDXXNC-RRFJBIMHSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-[(4-methylphenyl)methylamino]purin-9-yl]oxolan-3-ol Chemical compound C1=CC(C)=CC=C1CNC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)C1 HDYYTVPJWDXXNC-RRFJBIMHSA-N 0.000 claims 2
- OAXVHVJRITUJPE-NILFDRSVSA-N (2r,3s,5r)-5-[6-(1,3-benzodioxol-5-ylmethylamino)purin-9-yl]-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=C4OCOC4=CC=3)=C2N=C1 OAXVHVJRITUJPE-NILFDRSVSA-N 0.000 claims 2
- FJJIZCAHWSYEKX-NWANDNLSSA-N (2r,3s,5r)-5-[6-[(4-hydroxy-3-methoxyphenyl)methylamino]purin-9-yl]-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=C(O)C(OC)=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@@H]2O[C@H](CO)[C@@H](O)C2)=C1 FJJIZCAHWSYEKX-NWANDNLSSA-N 0.000 claims 2
- HBALHWFNUKBZNS-PLKNEFISSA-N 1-[(2r,3s,5r)-3-acetyl-3-hydroxy-5-[6-[(2-hydroxyphenyl)methylamino]purin-9-yl]oxolan-2-yl]-1-hydroxypropan-2-one Chemical compound C1[C@](C(C)=O)(O)[C@@H](C(O)C(=O)C)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=CC=3)O)=C2N=C1 HBALHWFNUKBZNS-PLKNEFISSA-N 0.000 claims 2
- KXDCEYZRXVDDKQ-KWGDYSOASA-N 1-[(2r,3s,5r)-3-acetyl-3-hydroxy-5-[6-[(4-hydroxy-3-methoxyphenyl)methylamino]purin-9-yl]oxolan-2-yl]-1-hydroxypropan-2-one Chemical compound C1=C(O)C(OC)=CC(CNC=2C=3N=CN(C=3N=CN=2)[C@@H]2O[C@@H]([C@@](O)(C2)C(C)=O)C(O)C(C)=O)=C1 KXDCEYZRXVDDKQ-KWGDYSOASA-N 0.000 claims 2
- PFQNGTINMSJNQP-KWGDYSOASA-N 1-[(2r,3s,5r)-3-acetyl-5-[6-(1,3-benzodioxol-5-ylmethylamino)purin-9-yl]-3-hydroxyoxolan-2-yl]-1-hydroxypropan-2-one Chemical compound C1[C@](C(C)=O)(O)[C@@H](C(O)C(=O)C)O[C@H]1N1C2=NC=NC(NCC=3C=C4OCOC4=CC=3)=C2N=C1 PFQNGTINMSJNQP-KWGDYSOASA-N 0.000 claims 2
- UAEMDTFGPRXKDS-NUWNTWNGSA-N 3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-[[(1R)-1-phenylpropyl]amino]purin-9-yl]oxolan-2-yl]-3-hydroxypropanoic acid Chemical compound CC[C@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CC(=O)O)O)O)O UAEMDTFGPRXKDS-NUWNTWNGSA-N 0.000 claims 2
- UAEMDTFGPRXKDS-FTANPALGSA-N 3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-[[(1S)-1-phenylpropyl]amino]purin-9-yl]oxolan-2-yl]-3-hydroxypropanoic acid Chemical compound CC[C@@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CC(=O)O)O)O)O UAEMDTFGPRXKDS-FTANPALGSA-N 0.000 claims 2
- NQLZSQVEXJAROU-JEDQKWKHSA-N 3-[(2R,3S,4R,5R)-5-[6-[(4-acetyloxy-3-methoxyphenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-3-hydroxypropanoic acid Chemical compound COC=1C=C(CNC=2C=3N=CN([C@H]4[C@H](O)[C@H](O)[C@@H](C(O)CC(=O)O)O4)C=3N=CN=2)C=CC=1OC(C)=O NQLZSQVEXJAROU-JEDQKWKHSA-N 0.000 claims 2
- JJSBILSSLHHKQS-GICMACPYSA-N 9-(oxolan-2-yl)-n-[(1r)-1-phenylpropyl]purin-6-amine Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2C1CCCO1 JJSBILSSLHHKQS-GICMACPYSA-N 0.000 claims 2
- JJSBILSSLHHKQS-MLCCFXAWSA-N 9-(oxolan-2-yl)-n-[(1s)-1-phenylpropyl]purin-6-amine Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2C1CCCO1 JJSBILSSLHHKQS-MLCCFXAWSA-N 0.000 claims 2
- NASPXVCXQJLNEL-FBPFPRGXSA-N 9-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-methoxy-4-octanoyloxyphenyl)methylamino]purin-9-yl]oxolan-2-yl]-9-hydroxynonanoic acid Chemical compound CCCCCCCC(=O)OC1=C(C=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CCCCCCCC(=O)O)O)O)O)OC NASPXVCXQJLNEL-FBPFPRGXSA-N 0.000 claims 2
- ANJMAQUPZQBFST-IRKLPRKNSA-N 9-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-[1-(3,4,5-trimethoxyphenyl)ethylamino]purin-9-yl]oxolan-2-yl]-9-hydroxynonanoic acid Chemical compound CC(C1=CC(=C(C(=C1)OC)OC)OC)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CCCCCCCC(=O)O)O)O)O ANJMAQUPZQBFST-IRKLPRKNSA-N 0.000 claims 2
- XJLBPMONRNUTCC-GQXHGVFDSA-N 9-[(2R,3S,4R,5R)-5-[6-(1,3-benzodioxol-5-ylmethylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-9-hydroxynonanoic acid Chemical compound C1OC2=C(O1)C=C(C=C2)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(CCCCCCCC(=O)O)O)O)O XJLBPMONRNUTCC-GQXHGVFDSA-N 0.000 claims 2
- JTKGROQXDPPDGF-CIVUBGFFSA-N C1=C(OC)C(OC(=O)CCC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound C1=C(OC)C(OC(=O)CCC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JTKGROQXDPPDGF-CIVUBGFFSA-N 0.000 claims 2
- NWBSEDZQPSWDMS-VJUOEERUSA-N C1=C(OC)C(OC(=O)CCCCCCC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound C1=C(OC)C(OC(=O)CCCCCCC)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NWBSEDZQPSWDMS-VJUOEERUSA-N 0.000 claims 2
- HXNKZFAZAIGIPD-WVSUBDOOSA-N O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NN3CCN(CC3)C=3C=CC=CC=3)=C2N=C1 Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NN3CCN(CC3)C=3C=CC=CC=3)=C2N=C1 HXNKZFAZAIGIPD-WVSUBDOOSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 2
- OPBOKLRORBKBAN-SECBINFHSA-N n-[(1r)-1-phenylethyl]-7h-purin-6-amine Chemical compound C1([C@H](NC=2C=3NC=NC=3N=CN=2)C)=CC=CC=C1 OPBOKLRORBKBAN-SECBINFHSA-N 0.000 claims 2
- RVHSEXOWWRYORG-LLVKDONJSA-N n-[(1r)-1-phenylpropyl]-7h-purin-6-amine Chemical compound C1([C@H](NC=2C=3NC=NC=3N=CN=2)CC)=CC=CC=C1 RVHSEXOWWRYORG-LLVKDONJSA-N 0.000 claims 2
- OPBOKLRORBKBAN-VIFPVBQESA-N n-[(1s)-1-phenylethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3NC=NC=3N=CN=2)C)=CC=CC=C1 OPBOKLRORBKBAN-VIFPVBQESA-N 0.000 claims 2
- RVHSEXOWWRYORG-NSHDSACASA-N n-[(1s)-1-phenylpropyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)=CC=CC=C1 RVHSEXOWWRYORG-NSHDSACASA-N 0.000 claims 2
- SSQVUUSLAFSAAE-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[4-(trifluoromethoxy)phenyl]methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C=CC(OC(F)(F)F)=CC=3)=C2N=C1 SSQVUUSLAFSAAE-LSCFUAHRSA-N 0.000 claims 1
- ABYSNGXHESJZAQ-ORGHYPSLSA-N 5-[(2R,3S,4R,5R)-5-[6-[(4-butanoyloxy-3-methoxyphenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-5-hydroxypentanoic acid Chemical compound CCCC(=O)OC1=C(C=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CCCC(=O)O)O)O)O)OC ABYSNGXHESJZAQ-ORGHYPSLSA-N 0.000 claims 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims 1
- UGVIXKXYLBAZND-UHFFFAOYSA-N T1-11 Natural products OC1C(O)C(CO)OC1N1C2=NC=NC(NCC=3C=CC(O)=CC=3)=C2N=C1 UGVIXKXYLBAZND-UHFFFAOYSA-N 0.000 claims 1
- 125000000101 thioether group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002082 anti-convulsion Effects 0.000 abstract description 2
- 239000003326 hypnotic agent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 241
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 217
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 203
- 239000002904 solvent Substances 0.000 description 146
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 120
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 112
- 150000002500 ions Chemical class 0.000 description 112
- 239000007787 solid Substances 0.000 description 110
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 104
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 98
- 125000003396 thiol group Chemical group [H]S* 0.000 description 90
- 238000006243 chemical reaction Methods 0.000 description 86
- 235000019439 ethyl acetate Nutrition 0.000 description 81
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 79
- 238000010898 silica gel chromatography Methods 0.000 description 77
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 75
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 64
- 239000011734 sodium Substances 0.000 description 64
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- 239000011541 reaction mixture Substances 0.000 description 59
- 239000002777 nucleoside Substances 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 125000006612 decyloxy group Chemical group 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 34
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 32
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 32
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 29
- 239000000706 filtrate Substances 0.000 description 29
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 28
- 238000005984 hydrogenation reaction Methods 0.000 description 25
- 125000001589 carboacyl group Chemical group 0.000 description 24
- 150000003254 radicals Chemical class 0.000 description 23
- 239000013078 crystal Substances 0.000 description 21
- KJSVAZNPHAQRIM-UHFFFAOYSA-N phenol;prop-1-ene Chemical group CC=C.OC1=CC=CC=C1 KJSVAZNPHAQRIM-UHFFFAOYSA-N 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 19
- 238000010828 elution Methods 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 17
- 235000019253 formic acid Nutrition 0.000 description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 125000000466 oxiranyl group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 8
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229910004373 HOAc Inorganic materials 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 150000002923 oximes Chemical class 0.000 description 7
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- HPPYASNQUZDNJB-UHFFFAOYSA-N 2,2-dimethoxypropanimidamide Chemical compound COC(C)(OC)C(N)=N HPPYASNQUZDNJB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 239000007810 chemical reaction solvent Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000003835 adenosine derivatives Chemical class 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 4
- 239000012964 benzotriazole Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- DLICLIIFPGEMAL-FNKNIWJNSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(3,4,5-trimethoxyphenyl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC=1C=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C3=NC=N2)N)C=C(C1OC)OC DLICLIIFPGEMAL-FNKNIWJNSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- YWCLXRYOKNLWCQ-UHFFFAOYSA-N 5-(2-aminoethyl)-2-methoxycyclohexa-3,5-diene-1,1,2-triol Chemical compound COC1(O)C=CC(CCN)=CC1(O)O YWCLXRYOKNLWCQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000305491 Gastrodia elata Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 3
- 239000004062 cytokinin Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- LZDSYIZUCSUNKJ-UHFFFAOYSA-N (2-methyl-1-phenylpropyl)azanium;chloride Chemical compound Cl.CC(C)C(N)C1=CC=CC=C1 LZDSYIZUCSUNKJ-UHFFFAOYSA-N 0.000 description 2
- UFTRQUIJKKGLEY-HUJIRHDGSA-N (2R,3R,4S,5R)-2-[6-amino-6-(1-phenylpropyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(=CC=CC=C1)C(CC)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N UFTRQUIJKKGLEY-HUJIRHDGSA-N 0.000 description 2
- NGOVJBTWRZVFSW-LETGHGJSSA-N (2R,3R,4S,5R)-2-[6-amino-6-(2-methylpropyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N=C2C(CC(C)C)(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NGOVJBTWRZVFSW-LETGHGJSSA-N 0.000 description 2
- HWYXCFNYIXCMOL-BYPQGEBLSA-N (2R,3R,4S,5R)-2-[6-amino-6-(4-phenylpiperazin-1-yl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(=CC=CC=C1)N1CCN(CC1)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N HWYXCFNYIXCMOL-BYPQGEBLSA-N 0.000 description 2
- ZDNHOWGTOHTYQV-REBVSCDPSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1S)-1-(4-nitrophenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)[C@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N ZDNHOWGTOHTYQV-REBVSCDPSA-N 0.000 description 2
- NYTBELIHLJDTQM-QEFUDJMMSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(4-methoxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC=C(C=C1)C(C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N NYTBELIHLJDTQM-QEFUDJMMSA-N 0.000 description 2
- SCZIYYYVGXOQBH-UUMXHZSTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(4-methoxyphenyl)propyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC=C(C=C1)C(CC)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N SCZIYYYVGXOQBH-UUMXHZSTSA-N 0.000 description 2
- VLJURLSEYALRQJ-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)methanamine;hydrochloride Chemical compound Cl.COC1=CC(CN)=CC(OC)=C1OC VLJURLSEYALRQJ-UHFFFAOYSA-N 0.000 description 2
- YMKCMLPZLUTFMS-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine;hydrochloride Chemical compound Cl.COC1=CC=C(CN)C=C1OC YMKCMLPZLUTFMS-UHFFFAOYSA-N 0.000 description 2
- PUDMGOSXPCMUJZ-UHFFFAOYSA-N (4-hydroxy-3-methoxyphenyl)methylazanium;chloride Chemical compound Cl.COC1=CC(CN)=CC=C1O PUDMGOSXPCMUJZ-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- JHNRZXQVBKRYKN-VQHVLOKHSA-N (ne)-n-(1-phenylethylidene)hydroxylamine Chemical compound O\N=C(/C)C1=CC=CC=C1 JHNRZXQVBKRYKN-VQHVLOKHSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- WYQUYSRUIVFEII-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound COC1=CC(C(C)N)=CC(OC)=C1OC WYQUYSRUIVFEII-UHFFFAOYSA-N 0.000 description 2
- WFWKNGZODAOLEO-UHFFFAOYSA-N 1-(4-Methoxyphenyl)-2-propanone Chemical compound COC1=CC=C(CC(C)=O)C=C1 WFWKNGZODAOLEO-UHFFFAOYSA-N 0.000 description 2
- ORRIKTBCHRPKCN-UHFFFAOYSA-N 1-(4-methoxyphenyl)butan-1-amine;hydrochloride Chemical compound Cl.CCCC(N)C1=CC=C(OC)C=C1 ORRIKTBCHRPKCN-UHFFFAOYSA-N 0.000 description 2
- FYLBCUWOAFIYOW-UHFFFAOYSA-N 1-(4-methoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.COC1=CC=C(C(C)N)C=C1 FYLBCUWOAFIYOW-UHFFFAOYSA-N 0.000 description 2
- SKIDNYUZJPMKFC-UHFFFAOYSA-N 1-iododecane Chemical compound CCCCCCCCCCI SKIDNYUZJPMKFC-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- QQNHRVKUNBTYKN-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]ethanamine Chemical compound CC(C)CC1=CC=C(CCN)C=C1 QQNHRVKUNBTYKN-UHFFFAOYSA-N 0.000 description 2
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- APHBPYXCRIYQAZ-XUGMROATSA-N 3-[(2R,3S,4R,5R)-5-[6-[(4-acetyloxy-3-methoxyphenyl)methyl]-6-amino-8H-purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-3-hydroxypropanoic acid Chemical compound COC=1C=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](C(O)CC(=O)O)O4)C3=NC=N2)N)C=CC1OC(C)=O APHBPYXCRIYQAZ-XUGMROATSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- HZURECLZXZPVOL-UHFFFAOYSA-N 4-(2-aminoethyl)-2-methoxycyclohexa-3,5-diene-1,1,2-triol Chemical compound COC1(O)C=C(CCN)C=CC1(O)O HZURECLZXZPVOL-UHFFFAOYSA-N 0.000 description 2
- BCVZHOXCSLFFBW-UHFFFAOYSA-N 4-(aminomethyl)-2,6-dimethoxyphenol;hydrochloride Chemical compound Cl.COC1=CC(CN)=CC(OC)=C1O BCVZHOXCSLFFBW-UHFFFAOYSA-N 0.000 description 2
- LFRARYNEDYNCOT-UHFFFAOYSA-N 4-(aminomethyl)benzene-1,2-diol;hydrochloride Chemical compound Cl.NCC1=CC=C(O)C(O)=C1 LFRARYNEDYNCOT-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 2
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 150000001454 anthracenes Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- NUFMSECAGOXHAV-XBXARRHUSA-N chembl1969186 Chemical compound O\N=C\C1=CC=C(O)C(O)=C1 NUFMSECAGOXHAV-XBXARRHUSA-N 0.000 description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 2
- ZIPQNVVCEHWMBV-UHFFFAOYSA-N furan-2-ylmethanamine;hydrochloride Chemical compound Cl.NCC1=CC=CO1 ZIPQNVVCEHWMBV-UHFFFAOYSA-N 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 125000006178 methyl benzyl group Chemical group 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- DUUBUZSEBKJTJH-UHFFFAOYSA-N n-(2-amino-1-phenylethylidene)hydroxylamine Chemical compound NCC(=NO)C1=CC=CC=C1 DUUBUZSEBKJTJH-UHFFFAOYSA-N 0.000 description 2
- ARLLNMVPNCXCIM-UHFFFAOYSA-N n-[(2-methylphenyl)methylidene]hydroxylamine Chemical compound CC1=CC=CC=C1C=NO ARLLNMVPNCXCIM-UHFFFAOYSA-N 0.000 description 2
- ANORDWOIBSUYBN-UHFFFAOYSA-N n-chloro-1-phenylmethanamine Chemical compound ClNCC1=CC=CC=C1 ANORDWOIBSUYBN-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000006502 nitrobenzyl group Chemical group 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 2
- DUDAKCCDHRNMDJ-UHFFFAOYSA-N thiophen-3-ylmethanamine Chemical compound NCC=1C=CSC=1 DUDAKCCDHRNMDJ-UHFFFAOYSA-N 0.000 description 2
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 2
- 235000021081 unsaturated fats Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- GCIHZDWTJCGMDK-UHFFFAOYSA-N (2-methylphenyl) prop-2-enoate Chemical compound CC1=CC=CC=C1OC(=O)C=C GCIHZDWTJCGMDK-UHFFFAOYSA-N 0.000 description 1
- MAYOSYLAZUGJGF-AXYPVASZSA-N (2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-2-ethyl-5-(hydroxymethyl)-3-phenyloxolane-3,4-diol Chemical compound C1(=CC=CC=C1)[C@@]1([C@@](O[C@@H]([C@H]1O)CO)(N1C=NC=2C(N)=NC=NC12)CC)O MAYOSYLAZUGJGF-AXYPVASZSA-N 0.000 description 1
- YNMADDFZZSQKAV-CDMSWCOPSA-N (2R,3R,4S,5R)-2-(6-amino-6-benzhydryl-8H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(=CC=CC=C1)C(C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N)C1=CC=CC=C1 YNMADDFZZSQKAV-CDMSWCOPSA-N 0.000 description 1
- FAIFWGKDQOGGSP-BEFMGFOSSA-N (2R,3R,4S,5R)-2-(6-amino-6-cyclohexyl-8H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N=C2C(N)(C3CCCCC3)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O FAIFWGKDQOGGSP-BEFMGFOSSA-N 0.000 description 1
- PGYXKNPHXNPTAO-VNOIWZSWSA-N (2R,3R,4S,5R)-2-[6-amino-6-(1,3-benzodioxol-5-ylmethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1OC=2C=C(CC3(C4=NCN([C@H]5[C@H](O)[C@H](O)[C@@H](CO)O5)C4=NC=N3)N)C=CC2O1 PGYXKNPHXNPTAO-VNOIWZSWSA-N 0.000 description 1
- YKCIYYUWAVKNMX-LUXJSJDUSA-N (2R,3R,4S,5R)-2-[6-amino-6-(1-phenylethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1(=CC=CC=C1)C(C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N YKCIYYUWAVKNMX-LUXJSJDUSA-N 0.000 description 1
- ABLWUKCCKAGXFT-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-(furan-2-ylmethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N1=CN=C2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)CN=C2C1(N)CC1=CC=CO1 ABLWUKCCKAGXFT-HIDXMTOYSA-N 0.000 description 1
- JHXNBNCXMRCTOC-HIDXMTOYSA-N (2R,3R,4S,5R)-2-[6-amino-6-(thiophen-2-ylmethyl)-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound S1C(=CC=C1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N JHXNBNCXMRCTOC-HIDXMTOYSA-N 0.000 description 1
- SHLQOKZYVWWTOM-RETCIDOPSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1R)-1-(4-chlorophenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC=C(C=C1)[C@@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N SHLQOKZYVWWTOM-RETCIDOPSA-N 0.000 description 1
- ZJYCQVWECKHBLD-RETCIDOPSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1R)-1-(4-fluorophenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound FC1=CC=C(C=C1)[C@@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N ZJYCQVWECKHBLD-RETCIDOPSA-N 0.000 description 1
- KGQWQXJUFSFXJW-NOFNQTTFSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1S)-1-(3-methoxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC=1C=C(C=CC1)[C@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N KGQWQXJUFSFXJW-NOFNQTTFSA-N 0.000 description 1
- SHLQOKZYVWWTOM-REBVSCDPSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1S)-1-(4-chlorophenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC=C(C=C1)[C@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N SHLQOKZYVWWTOM-REBVSCDPSA-N 0.000 description 1
- ZJYCQVWECKHBLD-REBVSCDPSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1S)-1-(4-fluorophenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound FC1=CC=C(C=C1)[C@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N ZJYCQVWECKHBLD-REBVSCDPSA-N 0.000 description 1
- JSDBILFZICGGGB-QSLJIQJKSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(1S)-1-(4-methylphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1=CC=C(C=C1)[C@H](C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N JSDBILFZICGGGB-QSLJIQJKSA-N 0.000 description 1
- OSXIKVQATZIYHV-IWKSVZPTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-chlorophenyl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=CC=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C3=NC=N2)N)C=C1 OSXIKVQATZIYHV-IWKSVZPTSA-N 0.000 description 1
- GWYXNTAORQZTNJ-IWKSVZPTSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-fluorophenyl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound FC1=CC=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C3=NC=N2)N)C=C1 GWYXNTAORQZTNJ-IWKSVZPTSA-N 0.000 description 1
- KWTVRHYDXJMRBO-AHQNTMFBSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC1=C(C=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C3=NC=N2)N)C=C1OC)OC KWTVRHYDXJMRBO-AHQNTMFBSA-N 0.000 description 1
- VRBPMRARYURDNB-VNOIWZSWSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(4-methylphenyl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1=CC=C(CC2(C3=NCN([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)C3=NC=N2)N)C=C1 VRBPMRARYURDNB-VNOIWZSWSA-N 0.000 description 1
- QMHDXMODRSGKGG-BEFMGFOSSA-N (2R,3R,4S,5R)-2-[6-amino-6-[(5-methylthiophen-2-yl)methyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound CC1=CC=C(S1)CC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N QMHDXMODRSGKGG-BEFMGFOSSA-N 0.000 description 1
- HADSDNIURYWKFV-QHZPWUFHSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(3,4,5-trimethoxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC=1C=C(C=C(C=1OC)OC)C(C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N HADSDNIURYWKFV-QHZPWUFHSA-N 0.000 description 1
- MBHSLUBXHZXEKO-OJUNHFKRSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(4-hydroxy-3-methoxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC=1C=C(C=CC1O)C(C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N MBHSLUBXHZXEKO-OJUNHFKRSA-N 0.000 description 1
- AYUMWKVLFAOFHZ-AMSHKJNMSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(4-hydroxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC1=CC=C(C=C1)C(C)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N AYUMWKVLFAOFHZ-AMSHKJNMSA-N 0.000 description 1
- JVMVYVSPEXUAQW-HUJIRHDGSA-N (2R,3R,4S,5R)-2-[6-amino-6-[1-(4-hydroxyphenyl)propyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC1=CC=C(C=C1)C(CC)C1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N JVMVYVSPEXUAQW-HUJIRHDGSA-N 0.000 description 1
- AQVZZFLICAXZLE-VNOIWZSWSA-N (2R,3R,4S,5R)-2-[6-amino-6-[2-(3,4-dihydroxyphenyl)ethyl]-8H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound OC=1C=C(C=CC1O)CCC1(C2=NCN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2=NC=N1)N AQVZZFLICAXZLE-VNOIWZSWSA-N 0.000 description 1
- BPPJDUPAHNSENM-YQBTWGSQSA-N (2r,3r,4s,5r)-2-(6-amino-6-chloro-8h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1N=C2C(N)(Cl)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BPPJDUPAHNSENM-YQBTWGSQSA-N 0.000 description 1
- IJRQTKBLHXUSEP-LSCFUAHRSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-[(2-nitrophenyl)methyl]oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(CC=2C(=CC=CC=2)[N+]([O-])=O)O[C@H](CO)[C@@H](O)[C@H]1O IJRQTKBLHXUSEP-LSCFUAHRSA-N 0.000 description 1
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- URVCVGNFSZHAOA-LSCFUAHRSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(2-hydroxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3C(=CC=CC=3)O)=C2N=C1 URVCVGNFSZHAOA-LSCFUAHRSA-N 0.000 description 1
- BDBYTVQXDMOPHD-CDUMDVBJSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[[(1r)-1-phenylbutyl]amino]purin-9-yl]oxolane-3,4-diol Chemical compound N([C@H](CCC)C=1C=CC=CC=1)C(C=1N=C2)=NC=NC=1N2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BDBYTVQXDMOPHD-CDUMDVBJSA-N 0.000 description 1
- AFIDBSSBLZSJMS-UHFFFAOYSA-N (5-methylfuran-2-yl)methanamine;hydrochloride Chemical compound Cl.CC1=CC=C(CN)O1 AFIDBSSBLZSJMS-UHFFFAOYSA-N 0.000 description 1
- XCBYYXLOEBELSB-UHFFFAOYSA-N (5-methylthiophen-2-yl)methanamine Chemical compound CC1=CC=C(CN)S1 XCBYYXLOEBELSB-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- VDAJDWUTRXNYMU-RUDMXATFSA-N (ne)-n-(1,3-benzodioxol-5-ylmethylidene)hydroxylamine Chemical compound O\N=C\C1=CC=C2OCOC2=C1 VDAJDWUTRXNYMU-RUDMXATFSA-N 0.000 description 1
- GASLBPLHYRZLLT-GQCTYLIASA-N (ne)-n-(thiophen-2-ylmethylidene)hydroxylamine Chemical compound O\N=C\C1=CC=CS1 GASLBPLHYRZLLT-GQCTYLIASA-N 0.000 description 1
- QVZGKUBQTJBLKI-IZZDOVSWSA-N (ne)-n-[(3,4,5-trimethoxyphenyl)methylidene]hydroxylamine Chemical compound COC1=CC(\C=N\O)=CC(OC)=C1OC QVZGKUBQTJBLKI-IZZDOVSWSA-N 0.000 description 1
- XXOHMWCSTKXDLH-JXMROGBWSA-N (ne)-n-[1-(4-methoxyphenyl)ethylidene]hydroxylamine Chemical compound COC1=CC=C(C(\C)=N\O)C=C1 XXOHMWCSTKXDLH-JXMROGBWSA-N 0.000 description 1
- PWCUVRROUAKTLL-PFONDFGASA-N (nz)-n-(1,2-diphenylethylidene)hydroxylamine Chemical compound C=1C=CC=CC=1C(=N/O)\CC1=CC=CC=C1 PWCUVRROUAKTLL-PFONDFGASA-N 0.000 description 1
- UYTMLDBQFLIQJA-XQRVVYSFSA-N (nz)-n-(furan-2-ylmethylidene)hydroxylamine Chemical compound O\N=C/C1=CC=CO1 UYTMLDBQFLIQJA-XQRVVYSFSA-N 0.000 description 1
- LGCDHCGMGDSSIO-GHXNOFRVSA-N (nz)-n-[1-(3,4,5-trimethoxyphenyl)ethylidene]hydroxylamine Chemical compound COC1=CC(C(\C)=N/O)=CC(OC)=C1OC LGCDHCGMGDSSIO-GHXNOFRVSA-N 0.000 description 1
- VTWKXBJHBHYJBI-VURMDHGXSA-N (nz)-n-benzylidenehydroxylamine Chemical compound O\N=C/C1=CC=CC=C1 VTWKXBJHBHYJBI-VURMDHGXSA-N 0.000 description 1
- OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 1
- GDNWCNZMRFWJPO-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine;hydrochloride Chemical compound Cl.NCC1=CC=C2OCOC2=C1 GDNWCNZMRFWJPO-UHFFFAOYSA-N 0.000 description 1
- PIJKTZVAKCFYNO-UHFFFAOYSA-N 1,5-bis[4-(2-methylpropyl)phenyl]pentan-3-one Chemical compound C(C(C)C)C1=CC=C(C=C1)CCC(=O)CCC1=CC=C(C=C1)CC(C)C PIJKTZVAKCFYNO-UHFFFAOYSA-N 0.000 description 1
- HNZNTXCLONMODT-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)ethylazanium;chloride Chemical compound Cl.COC1=CC(C(C)N)=CC(OC)=C1OC HNZNTXCLONMODT-UHFFFAOYSA-N 0.000 description 1
- PINPOEWMCLFRRB-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(Cl)C=C1 PINPOEWMCLFRRB-UHFFFAOYSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-UHFFFAOYSA-N 0.000 description 1
- MUUSKLMAQKVLKY-UHFFFAOYSA-N 1-(4-methoxyphenyl)butan-2-one Chemical compound CCC(=O)CC1=CC=C(OC)C=C1 MUUSKLMAQKVLKY-UHFFFAOYSA-N 0.000 description 1
- RAEVOBPXEHVUFY-UHFFFAOYSA-N 1-(4-nitrophenyl)ethanamine Chemical compound CC(N)C1=CC=C([N+]([O-])=O)C=C1 RAEVOBPXEHVUFY-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- GRVMJKAAXNELJW-UHFFFAOYSA-N 1-phenylpropan-1-amine;hydrochloride Chemical compound [Cl-].CCC([NH3+])C1=CC=CC=C1 GRVMJKAAXNELJW-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- KDYOFXPLHVSIHS-UHFFFAOYSA-N 2-(4-methylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(C)C=C1 KDYOFXPLHVSIHS-UHFFFAOYSA-N 0.000 description 1
- ORIHZIZPTZTNCU-UHFFFAOYSA-N 2-(hydroxyiminomethyl)phenol Chemical compound ON=CC1=CC=CC=C1O ORIHZIZPTZTNCU-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PGVVKQANLPHXOW-UHFFFAOYSA-N 2-methoxy-2-phenylpropanoic acid Chemical compound COC(C)(C(O)=O)C1=CC=CC=C1 PGVVKQANLPHXOW-UHFFFAOYSA-N 0.000 description 1
- XQQBUAPQHNYYRS-UHFFFAOYSA-N 2-methylthiophene Chemical compound CC1=CC=CS1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VUGQIIQFXCXZJU-UHFFFAOYSA-N 3,4,5-trimethoxyacetophenone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1OC VUGQIIQFXCXZJU-UHFFFAOYSA-N 0.000 description 1
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- HEOVGVNITGAUKL-UHFFFAOYSA-N 3-Methyl-1-phenyl-1-butanone Chemical compound CC(C)CC(=O)C1=CC=CC=C1 HEOVGVNITGAUKL-UHFFFAOYSA-N 0.000 description 1
- WTMFTEVPJUAVMR-CRXAZADBSA-N 3-[(2R,3S,4R,5R)-5-[6-amino-6-[(1R)-1-phenylpropyl]-8H-purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-3-hydroxypropanoic acid Chemical compound CC[C@H](C1=CC=CC=C1)C2(C3=NCN(C3=NC=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CC(=O)O)O)O)O)N WTMFTEVPJUAVMR-CRXAZADBSA-N 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NDZUMKRLIPIEQP-UHFFFAOYSA-N 4,10-dihydroxyperylene-3,9-dione Chemical group C1=CC2=C(C=CC3=O)C4C3=C(O)C=CC4C(C=CC3=O)=C2C3=C1O NDZUMKRLIPIEQP-UHFFFAOYSA-N 0.000 description 1
- WTJBBNOVSLEOFR-UHFFFAOYSA-N 4-(2-aminoethyl)cyclohexa-3,5-diene-1,1,2-triol Chemical group NCCC1=CC(O)C(O)(O)C=C1 WTJBBNOVSLEOFR-UHFFFAOYSA-N 0.000 description 1
- FPMWDMDLTSSKIU-UHFFFAOYSA-N 4-(2-hydroxyiminopropyl)phenol Chemical compound ON=C(C)CC1=CC=C(O)C=C1 FPMWDMDLTSSKIU-UHFFFAOYSA-N 0.000 description 1
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 1
- HWNAFGCZZCDVBB-BJMVGYQFSA-N 4-[(E)-hydroxyiminomethyl]-2,6-dimethoxyphenol Chemical compound COc1cc(\C=N\O)cc(OC)c1O HWNAFGCZZCDVBB-BJMVGYQFSA-N 0.000 description 1
- BVZSQTRWIYKUSF-TWGQIWQCSA-N 4-[(Z)-N-hydroxy-C-methylcarbonimidoyl]phenol Chemical compound C1=C(C=CC(=C1)O)/C(=N\O)/C BVZSQTRWIYKUSF-TWGQIWQCSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- VAUMDUIUEPIGHM-UHFFFAOYSA-N 5-Methyl-2-thiophenecarboxaldehyde Chemical compound CC1=CC=C(C=O)S1 VAUMDUIUEPIGHM-UHFFFAOYSA-N 0.000 description 1
- FCZOVUJWOBSMSS-UHFFFAOYSA-N 5-[(6-aminopurin-9-yl)methyl]-5-methyl-3-methylideneoxolan-2-one Chemical class C1=NC2=C(N)N=CN=C2N1CC1(C)CC(=C)C(=O)O1 FCZOVUJWOBSMSS-UHFFFAOYSA-N 0.000 description 1
- SXFFUSJFCFKISB-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)phenol hydrochloride Chemical compound Cl.OC1=C(C=CC(=C1)N)C1=CC=C(N)C=C1 SXFFUSJFCFKISB-UHFFFAOYSA-N 0.000 description 1
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 1
- HTLIXYXARPLOIU-UHFFFAOYSA-N 5-methylfuran-2-carboxamide Chemical compound CC1=CC=C(C(N)=O)O1 HTLIXYXARPLOIU-UHFFFAOYSA-N 0.000 description 1
- UZRQNAJRDUVHBX-UHFFFAOYSA-N 5-methylfuran-2-carboximidamide Chemical compound CC1=CC=C(C(N)=N)O1 UZRQNAJRDUVHBX-UHFFFAOYSA-N 0.000 description 1
- YTYIMDRWPTUAHP-UHFFFAOYSA-N 6-Chloroindole Chemical compound ClC1=CC=C2C=CNC2=C1 YTYIMDRWPTUAHP-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- PPUBJTKZHPXJLO-YPQNJCABSA-N 9-[(2R,3S,4R,5R)-5-[6-amino-6-[1-(3,4,5-trimethoxyphenyl)ethyl]-8H-purin-9-yl]-3,4-dihydroxyoxolan-2-yl]-9-hydroxynonanoic acid Chemical compound CC(C1=CC(=C(C(=C1)OC)OC)OC)C2(C3=NCN(C3=NC=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)C(CCCCCCCC(=O)O)O)O)O)N PPUBJTKZHPXJLO-YPQNJCABSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100269447 Arabidopsis thaliana AHK2 gene Proteins 0.000 description 1
- 101100269448 Arabidopsis thaliana AHK3 gene Proteins 0.000 description 1
- 101100269449 Arabidopsis thaliana AHK4 gene Proteins 0.000 description 1
- KJGLOIVGTHDWJL-UHFFFAOYSA-N C(C)(C)C(C)(NCC)C(C)C.NN Chemical compound C(C)(C)C(C)(NCC)C(C)C.NN KJGLOIVGTHDWJL-UHFFFAOYSA-N 0.000 description 1
- BDBHWZUFISUHAW-UHFFFAOYSA-N C1OC2C=C(C=CC2(N)O1)C1=CC=C(N)C=C1 Chemical compound C1OC2C=C(C=CC2(N)O1)C1=CC=C(N)C=C1 BDBHWZUFISUHAW-UHFFFAOYSA-N 0.000 description 1
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 description 1
- 101100096624 Caenorhabditis elegans srg-3 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100263202 Mus musculus Usp9x gene Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DDDIOEYMKVFUGK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methylazanium;chloride Chemical compound Cl.NCC1=CC=C(C(F)(F)F)C=C1 DDDIOEYMKVFUGK-UHFFFAOYSA-N 0.000 description 1
- NBFBFYBSYSJSPT-MCDZGGTQSA-N [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.ClC1=C2NC=NC2=NC=N1 Chemical compound [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12.ClC1=C2NC=NC2=NC=N1 NBFBFYBSYSJSPT-MCDZGGTQSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- CIHWJRSPVJBHGT-UHFFFAOYSA-N benzhydrylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(N)C1=CC=CC=C1 CIHWJRSPVJBHGT-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- RJJVVYVLHWMYAA-WEVVVXLNSA-N chembl202440 Chemical compound COC1=CC(\C=N\O)=CC=C1O RJJVVYVLHWMYAA-WEVVVXLNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 1
- BMFYCFSWWDXEPB-UHFFFAOYSA-N cyclohexyl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CCCCC1 BMFYCFSWWDXEPB-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- VGEWEGHHYWGXGG-UHFFFAOYSA-N ethyl n-hydroxycarbamate Chemical compound CCOC(=O)NO VGEWEGHHYWGXGG-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IZZGKDMJCDEZRA-UHFFFAOYSA-N n-(3-methyl-1-phenylbutylidene)hydroxylamine Chemical compound CC(C)CC(=NO)C1=CC=CC=C1 IZZGKDMJCDEZRA-UHFFFAOYSA-N 0.000 description 1
- FZIVKDWRLLMSEJ-UHFFFAOYSA-N n-[(2-chlorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=CC=CC=C1Cl FZIVKDWRLLMSEJ-UHFFFAOYSA-N 0.000 description 1
- XRUDLQMYHUIYOJ-UHFFFAOYSA-N n-[(5-methylthiophen-2-yl)methylidene]hydroxylamine Chemical compound CC1=CC=C(C=NO)S1 XRUDLQMYHUIYOJ-UHFFFAOYSA-N 0.000 description 1
- YHBLPZTWJHSSQB-UHFFFAOYSA-N n-[1-(4-methoxyphenyl)butan-2-ylidene]hydroxylamine Chemical compound CCC(=NO)CC1=CC=C(OC)C=C1 YHBLPZTWJHSSQB-UHFFFAOYSA-N 0.000 description 1
- XCAWVHHYSAGLPZ-UHFFFAOYSA-N n-[1-(4-methoxyphenyl)propan-2-ylidene]hydroxylamine Chemical compound COC1=CC=C(CC(C)=NO)C=C1 XCAWVHHYSAGLPZ-UHFFFAOYSA-N 0.000 description 1
- GBZLIAANNYDSOB-UHFFFAOYSA-N n-[[2-(trifluoromethyl)phenyl]methylidene]hydroxylamine Chemical compound ON=CC1=CC=CC=C1C(F)(F)F GBZLIAANNYDSOB-UHFFFAOYSA-N 0.000 description 1
- GVDONFUHZNOGQH-UHFFFAOYSA-N n-[cyclohexyl(phenyl)methylidene]hydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C1CCCCC1 GVDONFUHZNOGQH-UHFFFAOYSA-N 0.000 description 1
- DNYZBFWKVMKMRM-UHFFFAOYSA-N n-benzhydrylidenehydroxylamine Chemical compound C=1C=CC=CC=1C(=NO)C1=CC=CC=C1 DNYZBFWKVMKMRM-UHFFFAOYSA-N 0.000 description 1
- IYWYMFZAZUYNLC-UHFFFAOYSA-N n-benzylcyclohexanamine Chemical compound C=1C=CC=CC=1CNC1CCCCC1 IYWYMFZAZUYNLC-UHFFFAOYSA-N 0.000 description 1
- VFZWCTYGZWDQGK-UHFFFAOYSA-N n-benzylhexan-1-amine Chemical compound CCCCCCNCC1=CC=CC=C1 VFZWCTYGZWDQGK-UHFFFAOYSA-N 0.000 description 1
- YSNXOQGDHGUKCZ-UHFFFAOYSA-N n-benzylhydroxylamine;hydron;chloride Chemical compound Cl.ONCC1=CC=CC=C1 YSNXOQGDHGUKCZ-UHFFFAOYSA-N 0.000 description 1
- WZYBOBOXHKMFSI-UHFFFAOYSA-N n-benzylnitramide;hydrochloride Chemical compound Cl.[O-][N+](=O)NCC1=CC=CC=C1 WZYBOBOXHKMFSI-UHFFFAOYSA-N 0.000 description 1
- 125000006610 n-decyloxy group Chemical group 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- NAQQTJZRCYNBRX-UHFFFAOYSA-N n-pentan-3-ylidenehydroxylamine Chemical compound CCC(CC)=NO NAQQTJZRCYNBRX-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- LQNUZADURLCDLV-IDEBNGHGSA-N nitrobenzene Chemical group [O-][N+](=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 LQNUZADURLCDLV-IDEBNGHGSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940048346 phenethylamine hydrochloride Drugs 0.000 description 1
- QCCDLTOVEPVEJK-UHFFFAOYSA-N phenylacetone Chemical compound CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 1
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Definitions
- the present invention relates to N 6 -substituted adenosine derivatives and N 6 -substituted adenine derivatives, processes for their preparation, pharmaceutical compositions containing such compounds, and the preparation of such compounds for the preparation of sedative, hypnotic, anticonvulsant, antiepileptic
- the application in anti-Parkinson's disease, prevention and treatment of dementia drugs and health care products belongs to the field of medical technology. Background technique
- N 6 -substituted porphyrins and adenosine derivatives are substances with important biological activities, some of which are present in trace amounts in natural plants, as plant cytokinins promote plant cell division and differentiation, and promote seed germination. , bud differentiation, branch formation, and important biological functions such as chlorophyll and starch production, and are widely used in plant bioengineering technology research. Recent studies have found that histidine kinases, including AHK2, AHK3, and AHK4, act as receptors for cytokinins and play important roles in cytokinin signaling pathways.
- N 6 - isopentenyl reported derivative-substituted purine derivatives is relatively large, while N 6 - isopentenyl reported derivatives substituted nucleoside derivatives less.
- the research of such components in medical biology and its pharmacological activities is mainly focused on anti-tumor and anti-viral; at the same time, some people are deriving N 6 -phenyl substituted adenosine derivatives.
- N 6 -(4-hydroxybenzyl)-adenosine has been isolated from Gastrodia elata, and it has been found to prevent PC12 cell apoptosis and binding to adenosine A 2A receptor, but the compound and similar components are calmed.
- the role of central nervous system and mental system such as hypnosis has not been reported.
- Nai-Kuei Huang, Yijuang Chern, Jim-Min Fang, Chia-ILin, Wan-PingChen, and Yun-Lian Lin Neuroprotective Principles from Gastrodiaelata, J. Nat. Prod., 2007, 70, 571-574. (and the article bow
- a pharmaceutical composition comprising such a ⁇ 6 -substituted adenosine compound and a ⁇ 6 -substituted adenine compound is provided.
- the use of such a ⁇ 6 -substituted adenosine compound and a ⁇ 6 -substituted adenine compound is provided.
- the inventors of the present invention simultaneously isolated N6-(4-hydroxybenzyl group) having significant sedative and hypnotic effects from the extracts of Gastrodia elata and Ginseng ginseng by the activity tracking method in the process of studying the active ingredients of the traditional Chinese medicine Gastrodia elata and Ginseng ginseng.
- N6-substituted adenosine and the N6-substituted adenine compound described in the present invention are as shown in the formula (VI) and esters, stereoisomers, esters, ethers and pharmaceutically acceptable salts thereof:
- n is an integer selected from 0 to 4, preferably an integer of 1-3, more preferably an integer of 1-2
- a linear or branched aliphatic group selected from the group consisting of hydrogen ( ⁇ ) or substituted or unsubstituted C1-6;
- R is selected from hydrogen (H), hydroxy, substituted or unsubstituted C1-16 straight or branched fluorenyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 alkyl.
- COOR' is a carboxyl group (i.e., COOH); when R' is selected from a C1-6 alkyl group, COOR' is a C1-6 oxiranyl group.
- Z is selected from the group consisting of ribosyl, esterified ribosyl, etherified ribosyl, 2'-deoxyribosyl, esterified 2'-deoxyribosyl, etherified 2'-deoxyribosyl, tetrahydrofuranyl or substituted Or an unsubstituted fat base;
- Z is selected from the group consisting of ribose groups, esterified ribosyl groups, etherified ribose groups.
- n is not 0, that is, an integer selected from 1-4, and neither R nor X represents hydrogen (H), the configuration of the carbon atom to which they are attached includes W type and S type or R type or S. type.
- the group represented by I may also be selected from (5R)-5-carboxypyrrol-2-yl, (55 5-carboxypyrrol-2-yl, (5R)-5-hydroxymethylpyrrol-2-yl or (5S) a 5-hydroxymethylpyrrol-2-yl group, a substituted or unsubstituted phenyl piperazinyl group, an amino acid residue, an ester of an amino acid residue;
- I is an amino acid residue
- the amino acid may be any known amino acid residue, and the amino acid may be in the D configuration or the L configuration; preferably, the amino acid residue is selected from the group consisting of a phenylalanine residue, a tyrosine residue, and a tryptophan.
- the amino acid residue COOH may form an ester with any alcohol; preferably an ester formed with an alcohol of C1-16; more preferably an ester formed with an alcohol of C1-6; most preferably a methyl ester or an ethyl ester.
- the substituent represented may also be selected from a substituted or unsubstituted furanyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted pyrrolyl group, a substituted or unsubstituted imidazolyl group, a substituted or unsubstituted naphthyl group, a substituted or Unsubstituted tetrahydronaphthyl, substituted or unsubstituted indenyl, substituted or unsubstituted indenyl, substituted or unsubstituted C3-8 cyclodecyl.
- the above substituent group is selected from the group consisting of hydrazine, hydroxy (hydrazine), amino ( ⁇ 2 ), nitro ( ⁇ 0 2 ), phenyl (Ph), methylenedioxy (OCH 2 0), halogen, C1-16 , an alkyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a C1-16 alkanoyloxy group; a fluorenyl group of the above C1-16, a decyloxy group of C1-16, C1-
- the fluorenyl group of 16 thiol group, C1-16 decanoyl group, C1-16 decanoyloxy group may be linear or branched; substituted or unsubstituted, and further substituents are selected from the group consisting of 3 ⁇ 4, hydroxy and Amino group;
- Preferred substituents are selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 alkoxy, C1-10 thiol, C1 -10 decanoyl, C1-10 nonanoyloxy; the above C1-10 fluorenyl group, C1-10 alkoxy group, C1-10 thiol group, C1-10 decanoyl group, C1-10 decanoyloxy group
- the thiol group in the chain is linear or branched, substituted or unsubstituted, and Further substituents are selected from the group consisting of halogen, hydroxy and amino;
- substituents are selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 oxiranyl, C1-6 thiol, C1-6 Alkanoyl group, C1-6 alkanoyloxy group; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6,
- the fluorenyl group in the C1-6 decanoyl group, the C1-6 decanoyloxy group is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- the most preferred substituents are selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy Base, trifluoromethyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- R is selected from hydrogen (H), hydroxy, substituted or unsubstituted C1-16 linear or branched fluorenyl, substituted or unsubstituted C3-8 cyclodecyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 fluorenyl; further substituents on R are preferably from hydroxy, amino, nitro, methylenedioxy, halogen; further substituents are more preferably from hydroxy, urethane Dioxy, halogen; the most preferred of the further substituents is selected from the group consisting of hydroxyl groups.
- the parent nucleus of the compound may be attached to any suitably attached carbon atom on the furanyl group, i.e., by attachment to a carbon atom at the 2- or 3-position on the furanyl group.
- the parent nucleus of the compound may be attached to any suitably attached carbon atom on the thienyl group, i.e., via a carbon atom at the 2- or 3-position on the thienyl group.
- the parent nucleus of the compound may be attached to any suitably attached atom on the 2-pyrrolyl group, ie by attachment to a 2- or 3-position carbon atom on the 2-pyrrolyl group.
- 2-pyrrolyl, 3-pyrrolyl any suitably attached atom on the 2-pyrrolyl group, ie by attachment to a 2- or 3-position carbon atom on the 2-pyrrolyl group.
- the parent nucleus of the compound may be attached to any suitably attached atom on the naphthyl group, preferably to the carbon atom at the 1-position.
- the parent nucleus of the compound may be bonded to any suitably bonded atom on the tetrahydronaphthyl group, preferably to the carbon atom at the 1-position.
- the parent nucleus of the compound may be bonded to any suitably bonded atom on the fluorenyl group, preferably to the carbon atom at the 1-position, preferably to the atom at the 3-position.
- the parent nucleus of the compound may be bonded to any suitably bonded atom on the fluorenyl group, preferably to the atom at the 9 position of hydrazine.
- the parent nucleus of the compound can be attached to any suitably attached carbon atom on the cycloalkyl group.
- the position of the substituent group on the substituted phenyl group includes the 2 to 6 positions of the phenyl group; the number of the substituent groups on the substituted phenyl group includes 1 to 5; methylenedioxy group (OCH 2 0 )
- the preferred substitution position is the ortho position of the benzene ring.
- the branched fluorenyl group comprises a saturated branched aliphatic group of 1 to 16 carbon atoms and an unsaturated branched aliphatic group; wherein the number of branches of the branched chain is 1 to 2; the unsaturated group in the long chain of the unsaturated fat Including 1 to 4 unconjugated or conjugated double bonds, also including terminal triple bonds; the esterified ribose group or 2'-deoxyribose group refers to a hydroxy group on a ribose group or a 2'-deoxyribose group. Chemical.
- the acid used for esterification includes saturated fatty acids of 1 to 16 carbon atoms, unsaturated fatty acids (containing 1-4 unconjugated or conjugated double bonds or terminal triple bonds), phenylpropionic acid, p-toluene acrylic acid , p-hydroxyphenylpropionic acid, phenylacrylic acid, p-hydroxyphenylacrylic acid or ferulic acid;
- the position of the esterified hydroxyl group includes the 2', 3' and 5' positions of the ribose group; 2'-deoxyribose The 3' and 5' positions of the group are simultaneously esterified or selectively monoesterified or diesterified; the etherified ribosyl or etherified 2'-deoxyribosylribidosyl or 2'-deoxyribose
- the hydroxyl group on the group is etherified.
- the group used for etherification includes a saturated aliphatic group of 1 to 16 carbon atoms, an unsaturated aliphatic group (containing 1-4 unconjugated or conjugated double bonds or terminal triple bonds), phenylpropyl group, P-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropanyl, nitrophenyl; etherified sites including the 2', 3' and 5' positions of the ribose group Or the 3' and 5' positions of the 2'-deoxyribosyl group are simultaneously etherified or selectively monoetherified or bisetherified; preferred compounds of formula (VI) include, but are not limited to, the compounds of formula (I)
- R is selected from hydrogen ( ⁇ ), hydroxy, substituted or unsubstituted C1-16 straight or branched alkyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 alkyl;
- the group represented by I may also be selected from 5 -5-carboxypyrrol-2-yl, (;55 5-carboxypyrrol-2-yl, (5R)-5-hydroxymethylpyrrol-2-yl or (55 5 - an ester of a hydroxymethylpyrrol-2-yl group, a substituted or unsubstituted phenyl piperazinyl group, an amino acid residue, an amino acid residue;
- the substituent represented may also be selected from a substituted or unsubstituted furanyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted pyrrolyl group, a substituted or unsubstituted imidazolyl group, a substituted or unsubstituted naphthyl group, a substituted or An unsubstituted tetrahydronaphthyl group, a substituted or unsubstituted fluorenyl group, a substituted or
- the above further substituent group is selected from the group consisting of hydrazine, hydroxy (hydrazine), amino ( ⁇ 2), nitro ( ⁇ 02), phenyl (Ph), methylenedioxy (OCH20), halogen, and C1-16 fluorenyl group.
- the thiol group of the thiol group, the C1-16 alkanoyl group, the C1-16 alkanoyloxy group may be linear or branched; substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino .
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- R 2 , R 3 or R 5 are independently selected from C 7-12 saturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C7-12 saturated decanoyl group, phenylpropionyl group, p-hydroxyphenylpropionyl group, p-methylphenylpropionyl group, phenylacryloyl group, p-hydroxyphenylacryloyl group, nitrobenzoyl group;
- R2, R3 or R5 are independently selected from the group consisting of: propyl, o-nitrophenyl, C10H21, acetyl, propionyl, p-toluene acryloyl, p-methoxyphenylpropionyl, octanoyl, C
- R2 and R3 form a propylidene group.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (A)
- l selected from H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 alkanoyloxy group; the above fluorenyl group of C1-16, alkoxy group of C1-16, alkylthio group of C1-16, oxime of C1-16 decanoyl group, C1-16 alkanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (A) include, but are not limited to, the compounds of formula (Aa)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 oxiranyl, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above fluorenyl group of C1-10, a decyloxy group of C1-10, an alkylthio group of C1-10, a C1-10 alkanoyl group, a fluorene of C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated sulfhydryl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, c 7 -12 saturated Alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (Aa) include, but are not limited to, the compounds of formula (Aal)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 nonanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (Aa) include compounds represented by (Aa2)
- R1 and R2 are independently selected from H, C1-6 fluorenyl, C1-6 decanoyl;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated sulfhydryl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (A) include, but are not limited to, compounds of formula (Ab)
- Y is selected from the group consisting of hydrazine, C1-7 alkyl,
- R2, R3 and R5 are independently selected from hydrogen, C 7 _ 12 alkyl with saturated, phenylpropyl group, propyl p-hydroxybenzoate, p-phenylpropyl, phenyl-propenyl, propenyl, p-hydroxyphenyl, nitrophenyl And a C 7 -12 saturated alkanoyl group, a phenylpropionyl group, a p-hydroxyphenylpropionyl group, a p-methylphenylpropionyl group, a phenylacryloyl group, a p-hydroxyphenylacryloyl group, a nitrobenzoyl group, and R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (Ab) include, but are not limited to, the compounds of formula (Abl)
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxy
- the phenylacryloyl group, the nitrobenzoyl group, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include compounds represented by (B)
- W is selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom;
- 1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 alkoxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a fluorene group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (B) include, but are not limited to, compounds of formula (Ba)
- W is selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom;
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 alkoxy, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above C1-10 alkyl group, C1-10 decyloxy group, C1-10 sulfonylthio group,
- the fluorenyl group in the C1-10 decanoyl group, the C1-10 decanoyloxy group is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated sulfhydryl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (Ba) include, but are not limited to, compounds of formula (Bal)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 alkoxy, C1-6 thiol, C1-6 alkanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a decyloxy group of C1-6, an alkylthio group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Bal) include, but are not limited to, the compounds of the formula (Bal)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of the formula (Bal) include, but are not limited to, the compounds of the formula (Bal2)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of formula (Ba) include, but are not limited to, compounds of formula (Ba2)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 alkoxy, C1-6 thiol, C1-6 alkanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a decyloxy group of C1-6, an alkylthio group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Ba2) include, but are not limited to, the compounds of the formula (Ba21)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of the formula (Ba2) include, but are not limited to, the compounds of the formula (Ba22)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of formula (Ba) include, but are not limited to, compounds of formula (Ba3)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 oxiranyl, C1-6 thiol, C1-6 decanoyl, C1 -6 alkanoyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of a C1-6 alkanoyl group, and a C1-6 nonanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Ba3) include, but are not limited to, the compounds of the formula (Ba31)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of the formula (Ba3) include, but are not limited to, the compounds of the formula (Ba32)
- Rl is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (C)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a fluorene group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (D)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 alkyl, C1-16 decyloxy, C1-16 thiol, C1-16 alkane Acyl group, C1-16 alkanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, thiol group of C1-16, C1-16 decanoyl group, alkyl group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (E)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, alkoxy group of C1-16, thiol group of C1-16, oxime of C1-16 decanoyl group, C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (F)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 alkyl, C1-16 decyloxy, C1-16 thiol, C1-16 alkane Acyl group, C1-16 alkanoyloxy group; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 alkanoyl group, an alkane of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (G)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 alkyl, C1-16 alkoxy, C1-16 alkylthio, C1-16 alkane Acyl group, C1-16 decanoyloxy group; the above-mentioned C1-16 fluorenyl group, C1-16 decyloxy group, C1-16 thiol group, C1-16 alkanoyl group, C1-16 alkanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (H)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 alkylthio, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, alkoxy group of C1-16, thiol group of C1-16, oxime of C1-16 decanoyl group, C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (H) include, but are not limited to, compounds of formula (Ha)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 decyloxy, C1-10 alkylthio, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above C1-10 alkyl group, C1-10 decyloxy group, C1-10 thiol group, C1-10 alkanoyl group, C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated sulfhydryl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, c 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of the formula (Ha) include, but are not limited to, the compounds of the formula (Hal)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 decanoyl, C1 -6 alkanoyloxy; the above C1-6 fluorenyl group, C1-6 alkoxy group, C1-6 thiol group, C1-6 alkanoyl group, C1-6 decanoyloxy group in the alkyl group is straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (I) include compounds represented by (J)
- W is selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 alkoxy, C1-16 thiol, C1-16 alkane Acyl group, C1-16 nonanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, thiol group of C1-16, oxime of C1-16 decanoyl group, C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (J) include, but are not limited to, compounds of formula (Ja)
- W is selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom;
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 oxiranyl, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above-mentioned C1-10 fluorenyl group, C1-10 decyloxy group, C1-10 alkylthio group, C1-10 decanoyl group, C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- Preferred compounds of formula (J) include compounds represented by (Jal )
- W is selected from the group consisting of an oxygen atom, a sulfur atom, and a nitrogen atom;
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 oxiranyl, C1-6 thiol, C1-6 alkanoyl, C1 -6 alkanoyloxy; the above C1-6 alkyl group, C1-6 decyloxy group, C1-6 oxime thio group, C1-6 decanoyl group, C1-6 alkanoyloxy group fluorenyl group is straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (K)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above-mentioned C1-16 fluorenyl group, C1-16 decyloxy group, C1-16 thiol group, C1-16 decanoyl group, C1-16 alkanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (M)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, alkylthio group of C1-16, oxime of C1-16 decanoyl group, C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (N)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, alkylthio group of C1-16, C1-16 alkanoyl group, hydrazine in C1-16 alkanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (0)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a fluorene group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (P)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 nonanoyloxy group; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a fluorene group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated alkyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (Q)
- R is selected from the group consisting of Cl-4 fluorenyl, hydroxy-substituted Cl-4 fluorenyl;
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 alkoxy, C1-16 thiol, C1-16 ⁇ Acyl group, C1-16 alkanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, thiol group of C1-16, C1-16 decanoyl group, alkyl group of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (Q) include, but are not limited to, compounds of formula (Qa)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 oxiranyl, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above C1-10 alkyl group, C1-10 decyloxy group, C1-10 thiol group, C1-10 decanoyl group, C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, c 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (Qa) include, but are not limited to, compounds of formula (Qal)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 alkoxy, C1-6 thiol, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, C1-6 alkoxy group, C1-6 thiol group, C1-6 decanoyl group, C1-6 alkanoyloxy group fluorenyl group is straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Qal) include, but are not limited to, the compounds of the formula (al l )
- R1 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of the formula (Qal) include, but are not limited to, the compounds of the formula (al2)
- R1 is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methylthio, acetoxy, propionyloxy, trifluoro Methyl, trifluoromethoxy, fluoro, chloro, bromo, methylenedioxy.
- Preferred compounds of formula (Q) include, but are not limited to, compounds of formula (b)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 oxiranyl, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; above C1-10 alkyl group, C1-10 alkoxy group, C1-10 alkylthio group, C1-10 decanoyl group, C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (Qb) include, but are not limited to, compounds of formula (bl)
- (Qbl) R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 oxiranyl, C1-6 thiol, C1-6 alkanoyl, C1 -6 alkanoyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Qb) include compounds represented by (Qb2)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 thiol, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (Q) include, but are not limited to, compounds of formula (Qc)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-10 fluorenyl, C1-10 oxiranyl, C1-10 thiol, C1-10 ⁇ Acyl group, C1-10 nonanoyloxy group; the above-mentioned C1-10 fluorenyl group, C1-10 decyloxy group, C1-10 alkylthio group, C1-10 decanoyl group, C1-10 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, c 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (Qc) include, but are not limited to, compounds of formula (Qcl)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 oxiranyl, C1-6 thiol, C1-6 alkanoyl, C1 -6 alkanoyloxy; the above C1-6 alkyl group, C1-6 decyloxy group, C1-6 alkylthio group, C1-6 decanoyl group, C1-6 alkanoyloxy group fluorenyl group is straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Qc) include, but are not limited to, the compounds of the formula (Qc2)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 thiol, C1-6 alkanoyl, C1 -6 alkanoyloxy; the above fluorenyl group of C1-6, a decyloxy group of C1-6, an alkylthio group of C1-6, a C1-6 alkanoyl group, and a fluorenyl group of a C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (R)
- R6 and R7 are independently selected from C1-4 fluorenyl, hydroxy-substituted C1-4 fluorenyl;
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 alkyl, C1-16 decyloxy, C1-16 thiol, C1-16 alkane Acyl group, C1-16 nonanoyloxy group; alkyl group of the above C1-16, alkoxy group of C1-16, thiol group of C1-16, oxime of C1-16 decanoyl group, C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, Phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (R) include, but are not limited to, compounds of formula (Ra)
- R6 and R7 are independently selected from the group consisting of a hydroxyl group and a hydroxymethyl group
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 decyloxy, C1-6 thiol, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above C1-6 fluorenyl group, C1-6 alkoxy group, C1-6 thiol group, C1-6 decanoyl group, C1-6 decanoyloxy group in the alkyl group is straight Chain or branched, substituted or unsubstituted, and further substituents selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (R) include compounds represented by (Rb)
- R6 and R7 are independently selected from hydroxy, hydroxymethyl
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, C1-6 alkoxy group, C1-6 thiol group, C1-6 alkanoyl group, C1-6 alkanoyloxy group fluorenyl group is straight Chain or branched, substituted or unsubstituted, and further substituents selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 - 12 saturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (S)
- X is selected from substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl;
- R1 and a substituent on the cyclohexyl group and the phenyl group are independently selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol group, C1-16 alkanoyl group, C1-16 decanoyloxy group; the above C1-16 fluorenyl group, C1-16 decyloxy group, C1-16 thiol group, C1-16 ⁇ The fluorenyl group in the acyl group, C1-16 decanoyloxy group is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxyl and amino;
- R2, R or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (S) include, but are not limited to, the compounds of formula (Sa)
- Rl and n Rl ' independently selected from H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 decyloxy, C1-6 alkylthio, C1 -6 decanoyl, C1-6 nonanoyloxy; the above C1-6 fluorenyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 decanoyl, C1-6 nonanoyloxy
- the thiol group in the chain is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of the formula (Sa) include, but are not limited to, the compounds of the formula (Sal)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 fluorenyl, C1-6 alkoxy, C1-6 thiol, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of the formula (Sa) include compounds represented by (Sa2)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 thiol, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above fluorenyl group of C1-6, a fluorenyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, and C1-6 decanoyloxy group are straight Chain or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino.
- Preferred compounds of formula (I) include, but are not limited to, compounds of formula (T)
- Rl is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 alkyl, C1-16 decyloxy, ⁇ thio group of Cl-16, Cl-16 alkanoyl group, C1-16 decanoyloxy group; sulfhydryl group of above C1-16, decyloxy group of C1-16, alkylthio group of C1-16, C1-16 ⁇ The alkyl group in the acyl group, C1-16 alkanoyloxy group is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (T) include, but are not limited to, compounds of formula (Ta)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 decanoyl, C1 -6 ⁇ acyloxy; the above C1-6 alkyl group, C1-6 decyloxy group, C1-6 alkylthio group, C1-6 decanoyl group, C1-6 decanoyloxy group fluorenyl group is straight Chain or branched, substituted or unsubstituted, and further substituents selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 -12 saturated alkyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Alkanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (T) include, but are not limited to, compounds of formula (Tb)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, methylenedioxy, halogen, C1-6 alkyl, C1-6 decyloxy, C1-6 alkylthio, C1-6 alkanoyl, C1 -6 alkanoyloxy; the above fluorenyl group of C1-6, a decyloxy group of C1-6, a thiol group of C1-6, a fluorenyl group of C1-6 decanoyl group, C1-6 nonanoyloxy group is straight Chain or branched, substituted or unsubstituted, and further substituents selected from the group consisting of halogen, hydroxy and amino;
- R5 is selected from the group consisting of hydrogen, C 7 - 12 saturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C 7 -12 saturated Decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (I) include, but are not limited to, the compounds of formula (U)
- AA is an amino acid
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred AA is selected from
- Phenylalanine, tyrosine, tryptophan, histidine, proline, valine, threonine, serine, tryptophan, glycine, prolinol, preferred compounds of formula (VI) include but not Limited to compounds shown in formula (II)
- R1 is selected from the group consisting of H, hydroxy, amino, nitro, phenyl, methylenedioxy, halogen, C1-16 fluorenyl, C1-16 decyloxy, C1-16 thiol, C1-16 ⁇ Acyl, C1-16 alkanoyloxy; the above fluorenyl group of C1-16, a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a fluorene of C1-16 decanoyloxy group a radical is straight or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R2, R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated fluorenyl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxybenzene Propylene, nitrophenyl, C1-616 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, Nitrobenzoyl, R2 and R3 may be bonded to each other to form a ring.
- Preferred compounds of formula (VI) include, but are not limited to, compounds of formula (III)
- n is an integer selected from 0-4,
- X is selected from substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted naphthyl, substituted or unsubstituted tetrahydro Naphthyl, substituted or unsubstituted indenyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted indenyl, substituted or unsubstituted imidazole, substituted or unsubstituted I-indole, substituted or unsubstituted a linear or branched fluorenyl group of C3-8 cyclodecyl, substituted or unsubstituted C1-16;
- a linear or branched aliphatic group selected from the group consisting of hydrogen (hydrazine) or substituted or unsubstituted C1-6;
- R is selected from hydrogen ( ⁇ ), hydroxy, substituted or unsubstituted C1-16 linear or branched fluorenyl, substituted or unsubstituted C3-8 cyclodecyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 fluorenyl;
- the group may also be selected from (5-5-carboxypyrrol-2-yl, (55 5-carboxypyrrol-2-yl, (5R)-5-hydroxymethylpyrrol-2-yl or (55)-5 - an ester of a hydroxymethylpyrrol-2-yl group, a substituted or unsubstituted phenyl piperazinyl group, an amino acid residue, an amino acid residue;
- the substituent represented may also be selected from a substituted or unsubstituted furanyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted pyrrol
- the above further substituent is selected from the group consisting of H, a hydroxyl group, an amino group, a nitro group, a phenyl group, a methylenedioxy group, a halogen, a C1-16 alkyl group, a C1-16 decyloxy group, and a C1-16 alkyl sulfide.
- the alkyl group in the acyloxy group is linear or branched, substituted or unsubstituted, and further substituents are selected from the group consisting of halogen, hydroxy and amino;
- R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, phenylpropenyl, p-hydroxyphenylpropenyl , nitrophenyl, C1-16 saturated decanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl, p-hydroxyphenylacryloyl, nitro Benzoyl group.
- Preferred compounds of formula (III) include, but are not limited to, the compounds shown by ( ⁇ )
- R3 or R5 are independently selected from the group consisting of hydrogen, C1-16 saturated sulfhydryl, C1-16 unsaturated fluorenyl, phenylpropyl, p-hydroxyphenylpropyl, p-methylphenylpropyl, Phenylpropenyl, p-hydroxyphenylpropenyl, nitrophenyl, C1-16 saturated alkanoyl, C1-16 unsaturated decanoyl, phenylpropionyl, p-hydroxyphenylpropionyl, p-methylphenylpropionyl, phenylacryloyl , p-hydroxyphenylacryloyl, nitrobenzoyl.
- Preferred compounds of formula (VI) include, but are not limited to, the compounds of formula (IV)
- n is an integer selected from 0-4,
- X is selected from substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted naphthyl, substituted or unsubstituted tetrahydro Naphthyl, substituted or unsubstituted indenyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted indenyl, substituted or unsubstituted imidazole, substituted or unsubstituted I-indole, substituted or unsubstituted a linear or branched fluorenyl group of C3-8 cyclodecyl, substituted or unsubstituted C1-16;
- a linear or branched aliphatic group selected from the group consisting of hydrogen (hydrazine) or substituted or unsubstituted C1-6;
- R is selected from hydrogen ( ⁇ ), hydroxy, substituted or unsubstituted C1-16 linear or branched fluorenyl, substituted or unsubstituted C3-8 cyclodecyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 alkyl;
- the group represented by I may also be selected from (5ii)-5-carboxypyrrol-2-yl, (55 5-carboxypyrrol-2-yl, (5-5-hydroxymethylpyrrol-2-yl or (55) a 5-hydroxymethylpyrrol-2-yl group, a substituted or unsubstituted phenyl piperazinyl group, an amino acid residue, an ester of an amino acid residue;
- the substituent represented may also be selected from a substituted or unsubstituted furanyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted pyrrolyl group, a substituted or unsubstituted imidazolyl group, a substituted or unsubstituted naphthyl group, a substituted or Unsubstituted tetrahydronaphthyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted fluorenyl
- n is an integer selected from 0-4,
- X is selected from substituted or unsubstituted phenyl, substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted naphthyl, substituted or unsubstituted tetrahydro Naphthyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted imidazole, substituted or unsubstituted anthracene, substituted or unsubstituted C3- a linear or branched fluorenyl group of 8 ring fluorenyl, substituted or unsubstituted C1-16;
- Y is selected from hydrogen (H) or a substituted or unsubstituted C1-6 linear or branched aliphatic group
- R is selected from hydrogen (H), hydroxy, substituted or unsubstituted C1-16 straight or branched fluorenyl, substituted or unsubstituted C3-8 cyclodecyl, substituted or unsubstituted phenyl (Ph) , COOR' and R' are selected from hydrogen or C1-6 fluorenyl;
- the group may also be selected from carboxypyrrol-2-yl, (;55 5-carboxypyrrol-2-yl, (5R)-5-hydroxymethylpyrrol-2-yl or (55)-hydroxymethylpyrrole a 2-yl, substituted or unsubstituted phenyl piperazinyl group, an amino acid residue, an ester of an amino acid residue;
- the substituent represented may also be selected from a substituted or unsubstituted furanyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted pyrrolyl group, a substituted or
- the above further substituent group is selected from the group consisting of H, hydroxy (OH), amino (NH 2 ), nitro (N0 2 ), phenyl (Ph), methylenedioxy (OCH 2 0), halogen, C1- a fluorenyl group of 16 , a decyloxy group of C1-16, a thiol group of C1-16, a C1-16 decanoyl group, a C1-16 decanoyloxy group; a fluorenyl group of the above C1-16, a decyloxy group of C1-16
- the thiol group of C1-16, the fluorenyl group of the C1-16 alkanoyl group, the C1-16 alkanoyloxy group may be linear or branched; substituted or unsubstituted, and further substituents are selected from halogen , hydroxyl and amino groups.
- 6-chloropurine which can be passed through hypoxanthine (6-hydroxyl group) according to the method in the literature (LaMontagne and Maurice P., Journal of Heterocyclic Chemistry 1983, 20, 295).
- 6- chloropurine riboside according to the literature can be of Medicinal Chemistry (LakshmiP.Kotra, KonstantineK Manouilov, Journal 1996 , method 39, 5202) in muscle Glycosides are synthesized by reaction with S0 2 C1 2 ; or purchased directly from reagent companies (Sigma, Aldnch, Fluka, etc.); 6-bromoindole-2'-deoxynucleosides, according to the literature (Eduardo A. Veliz, Peter A. Beal) , J. Org. Chem. 2001, 66, 8592-8598), by reaction of 3',5'-diacetyl-adenine-2'-deoxynucleoside with tert-butyl nitrite and tribromoformamidine Synthetic.
- the second raw material for synthesizing the above compounds is an aldehyde, a ketone or an amine which can be commercially purchased.
- the basic procedure of the first method is as follows: In the first step, various aldehyde derivatives and hydroxylamine hydrochloride are stirred in an alcohol solvent at room temperature in the presence of anhydrous sodium acetate. The reaction solvent is evaporated to dryness, dissolved or suspended with water, and extracted with ethyl acetate. In the second step, the hydrazine of the various aldehyde derivatives obtained in the first step is dissolved in an alcohol, added with Pd/C, and hydrogenated under normal pressure in the presence of concentrated hydrochloric acid; the reaction solution is filtered, and the filtrate is concentrated to obtain the corresponding amine derivative of hydrochloric acid.
- the hydrazine of the various aldehyde derivatives obtained in the first step is dissolved in glacial acetic acid, added with zinc powder, and reduced to obtain the corresponding amine derivative.
- the hydrochloride of the amine derivative or the amine derivative is dissolved in the alcohol, and 6-chloropurine nucleoside (or 6-chloropurine or N 9 -substituted 6-chloropurine or 3', 5' is added.
- 6-chloropurine nucleoside or 6-chloropurine or N 9 -substituted 6-chloropurine or 3', 5' is added.
- 6-chloropurine nucleoside or 6-chloropurine or N 9 -substituted 6-chloropurine or 3', 5' is added.
- 6-chloropurine nucleoside or 6-chloropurine or N 9 -substituted 6-chloropurine or 3', 5' is added.
- the basic steps of the second method are: first step, benzotriazole, benzaldehyde derivative and adenosine, heating in the presence of an anhydrous alcohol and a catalytic acid; the reaction liquid is evaporated to remove the solvent, and then recrystallized Or chromatographic separation of a white solid.
- the white solid obtained in the first step was heated with NaBH 4 in anhydrous tetrahydrofuran. After cooling the reaction mixture to room temperature, it was poured into an ice-water mixture, neutralized with acid, and extracted with chloroform. After the chloroform layer is recovered and dissolved, the target product is obtained by recrystallization or chromatography.
- the N 6 -substituted adenosine derivative obtained by the above procedure is prepared by reacting with an acid anhydride or an acid chloride in pyridine.
- Monoester or diester compound, N 6 -substituted adenosine derivative reacts with 2,2-di-methoxypropionamidine in acetone to protect the 2,3-position on ribose, then catalyzed by EDCI and DMAP
- the esterification reaction is carried out with the corresponding acid, and finally the reaction group is removed by reaction in an aqueous solution of formic acid.
- Another object of the present invention is to provide a N 6 -substituted adenosine derivative and an N 6 -substituted adenine derivative, and a process for the preparation thereof, which comprises a therapeutically effective amount of the N 6 -substituted gland of the present invention
- a glycoside derivative and an N 6 -substituted adenine derivative, and optionally a pharmaceutically acceptable carrier are provided.
- the pharmaceutical carrier commonly used in the pharmaceutical field is a pharmaceutical carrier; the preparation method of the composition is a conventional pharmaceutical preparation method in the pharmaceutical field.
- a further aspect of the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention as an active ingredient.
- the pharmaceutical composition can be prepared according to methods well known in the art. Any dosage form suitable for human or animal use can be prepared by combining a compound of the invention with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants.
- the content of the compound of the present invention is usually from 0.1 to 95% by weight.
- the compound of the present invention or a pharmaceutical composition containing the same may be administered in a unit dosage form, which may be enterally or parenterally, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eye, lung, and Respiratory tract, skin, vagina, rectum, etc.
- the dosage form can be a liquid dosage form, a solid dosage form or a semi-solid dosage form.
- Liquid dosage forms can be solutions (including true and colloidal solutions), emulsions (including o/w, w/o and double emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops Agents, nasal drops, lotions, tinctures, etc.; solid dosage forms can be tablets (including plain tablets, enteric tablets, tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules ( Including hard capsules, soft capsules, enteric capsules), granules, powders, pellets, dropping pills, suppositories, films, patches, gas (powder) sprays, sprays, etc.; semi-solid dosage forms can be ointments, Gel, paste, etc.
- the compounds of the present invention can be formulated into common preparations, as sustained release preparations, controlled release preparations, targeted preparations, and various microparticle delivery systems.
- diluents may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.
- humectant may be water, ethanol, or different Propyl alcohol, etc.
- the binder may be starch pulp, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic, gelatin paste, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl Cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.
- disintegrant can be dry starch, microcrystalline cellulose, low
- Tablets may also be further formulated into coated tablets such as sugar coated tablets, film coated tablets, enteric coated tablets, or bilayer tablets and multilayer tablets.
- the active ingredient compound of the present invention may be mixed with a diluent, a glidant, and the mixture may be directly placed in a hard capsule or a soft capsule.
- the active ingredient can also be formulated into a granule or pellet with a diluent, a binder, a disintegrant, and then placed in a hard or soft capsule.
- the various diluents, binders, wetting agents, disintegrants, glidant varieties used to prepare the tablets of the compounds of the invention are also useful in the preparation of capsules of the compounds of the invention.
- water, ethanol, isopropanol, propylene glycol or a mixture thereof may be used as a solvent.
- the solubilizing agent or co-solvent may be poloxamer, lecithin, hydroxypropyl- ⁇ -cyclodextrin, etc.; pH adjusting agent may be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; osmotic pressure regulating agent may It is sodium chloride, mannitol, glucose, phosphate, acetate, and the like.
- mannitol, glucose or the like may also be added as a proppant.
- coloring agents may also be added to the pharmaceutical preparations as needed.
- the pharmaceutical or pharmaceutical composition of the present invention can be administered by any known administration method for the purpose of enhancing the therapeutic effect for the purpose of administration. Accordingly, it is another object of the present invention to provide the use of the ⁇ 6 -substituted adenosine derivatives and ⁇ 6 -substituted adenine derivatives of the present invention in the field of pharmaceuticals and health care products, particularly the ⁇ 6 -substituted adenosine of the present invention.
- ⁇ 6 -substituted adenosine of the present invention derivatives and ⁇ 6 - substituted adenine derivatives are useful for treating sedative and hypnotic, antidepressant, anticonvulsant, antiepileptic, anti-Parkinson's disease and prevention of dementia diseases, in particular sedative-hypnotic, antidepressant, anticonvulsant, anti- Epilepsy against Parkinson's disease and drugs and health supplements for the prevention and treatment of dementia diseases.
- the administration amount thereof can be referred to the use of the ⁇ 6 -substituted adenosine derivative and The amount of the ⁇ 6 -substituted adenine derivative to be treated; the ⁇ 6 -substituted adenosine derivative of the present invention and the ⁇ 6 -substituted adenine derivative or the composition of the present invention are used as a health supplement, or When adding a health supplement, the amount should be less than the usual amount of treatment.
- the pharmaceutical composition of the present invention can be administered in a wide range of dosages depending on the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route of administration and the dosage form, and the like.
- a suitable daily dose of the compound of the present invention is from 0.001 to 150 mg/kg body weight, preferably from 0.1 to 100 mg/kg body weight, more preferably from 1 to 60 mg/kg body weight, most preferably from 2 to 30 mg. /Kg weight.
- the above dosages may be administered in one dosage unit or in divided dose units depending on the clinical experience of the physician and the dosage regimen including the use of other therapeutic means.
- the compounds or compositions of the invention may be administered alone or in combination with other therapeutic or symptomatic agents.
- the compound of the present invention synergizes with other therapeutic agents, its dosage should be adjusted according to the actual situation. Detailed ways
- benzaldehyde (1.08 g), hydroxylamine hydrochloride (1.29 g) and anhydrous sodium acetate (1.67 g) were weighed and dissolved in ethanol (40 mL). The reaction was stirred at room temperature for 6 h. The solvent was recovered from the reaction solution. (20 mL) was dissolved in EtOAc (EtOAc) (EtOAc)
- benzaldehyde oxime (1.13 g) is dissolved in ethanol (40 mL), 10% Pd/C (85 mg) and concentrated hydrochloric acid (1 mL) are added, and hydrogenation is carried out at normal pressure; the reaction solution is filtered to remove Pd/C, and the filtrate is concentrated.
- White crystal benzylamine hydrochloride (1.29 g) was obtained.
- benzylamine hydrochloride (355 mg) was dissolved in n-propanol (40 mL), 6-chloropurine nucleoside (143 mg) and W, N-diisopropylethylamine (2 mL) , heating to 70 ° C, reaction for 8 h ; the solvent was recovered from the reaction mixture, which was separated by silica gel column chromatography eluting with chloroform-methanol (30:1) to give a colorless solid N 6 -(benzyl)-adenosine (151 Mg ) : positive ion ESIMS M/Z 358 [M + H] + ; negative ion ESIMS mlz 356 [M - H] - and 392 [M + CI]"; H NMR (300 MHz, CD 3 OD): adenosine Section 8.20 (1H, s, H-2), 8.18 (IH, brs, H-8), 5.90 (IH,
- hydroxybenzaldehyde (2.55 g), hydroxylamine hydrochloride (2.60 g) and anhydrous sodium acetate (3.40 g) were weighed and dissolved in ethanol (80 mL). The reaction was stirred at room temperature for 6 h; Dissolve in water (40 mL) and extract with ethyl acetate
- hydroxybenzaldehyde oxime (2.66g) is dissolved in ethanol (70mL), 10% Pd/C (300 mg) and concentrated hydrochloric acid (8mL) are added, hydrogenation at normal pressure; the reaction solution is filtered to remove Pd/C, filtrate The white crystalline hydroxybenzylamine hydrochloride (3.02 g) was obtained.
- hydroxybenzidine hydrochloride (3.02 g) was dissolved in n-propanol (70 mL), and 6-chloropurine nucleoside (1 g) and W,N-diisopropylethylamine were added.
- 0-hydroxybenzaldehyde oxime (1.0 g) was dissolved in EtOH (50 mL), 10% Pd/C (150 mg) and concentrated hydrochloric acid (2.8 mL) were added, and hydrogenation was carried out at normal pressure; C, the filtrate evaporated, suspended with ethyl acetate and dissolved, and filtered to give a white solid 0 - methylamine hydrochloride-hydroxybenzotriazole (l.lg).
- 0-hydroxybenzylamine hydrochloride (223 mg) was dissolved in n-propanol (60 mL), 6-chloropurine nucleoside (200 mg) and triethylamine (3 mL) were added and heated to 70 ° C, reaction for 8h; after recovering the solvent from the reaction solution, it is separated by silica gel column chromatography, using chloroform-methanol
- methyl benzaldehyde oxime (2.02g) is dissolved in EtOH (50mL), force!] 10% Pd/C (318mg) and concentrated hydrochloric acid (6mL), hydrogenation at normal pressure; reaction liquid filtration to remove Pd/C After the filtrate was evaporated to dryness, ethyl acetate was evaporated and evaporated to ethylamine.
- methylbenzylamine hydrochloride (221 mg) was dissolved in n-propanol (60 mL), 6-chloropurine nucleoside (200 mg) and triethylamine (3 mL) were added and heated to 70 ° C.
- methyl benzaldehyde oxime (1.2g) was dissolved in EtOH (50mL), 10% Pd/C (188mg) and concentrated hydrochloric acid (3.6mL) were hydrogenated at normal pressure; the reaction solution was filtered to remove Pd/C. After the filtrate was evaporated to dryness, ethyl acetate was evaporated and evaporated to ethylamine.
- the first step product (105 mg) was placed in a 100 mL three-necked flask, NaBH 4 (46 mg) and anhydrous tetrahydrofuran (60 mL) were added, and the mixture was heated and refluxed for 8 h; the reaction solution was cooled to room temperature and poured. The mixture was poured into an ice-water mixture, neutralized with acetic acid, and extracted with chloroform.
- chlorobenzaldehyde oxime (2.45g) was dissolved in HOAc (25mL), Zn powder (6.15g) was added, and stirred at room temperature for 6h; the reaction solution was filtered to remove excess Zn powder and ZnOAc precipitate, and the filtrate was evaporated to dry HOAc solution. A yellow oily chlorobenzylamine (1.25 g) was obtained.
- fluorobenzaldehyde oxime (1.8g) is dissolved in HOAc (25mL), and Zn powder (5.05g) is stirred at room temperature for 6h; 6 ⁇
- the first step weigh benzotriazole (148 mg), cyclohexylformaldehyde (168 mg) and adenosine (251 mg) in a 100 mL three-necked flask, add absolute ethanol (40 mL) and a catalytic amount of glacial acetic acid. , adding the addition funnel (with 4A molecular sieve), connected to the condenser, heating and refluxing for 14h; the reaction liquid recovers the solvent to obtain a viscous liquid, which is separated by silica gel column chromatography and eluted with chloroform-methanol (30:1 ⁇ 15:1) , 219 mg of a white solid.
- the first step product (152 mg) was placed in a 100 mL three-necked flask, NaBH 4 (73 mg) and anhydrous tetrahydrofuran (60 mL) were added, and the mixture was heated and refluxed for 8 h; the reaction solution was cooled to room temperature and poured. The mixture was poured into an ice-water mixture, neutralized with acetic acid, and extracted with chloroform.
- N-phenylpiperidine (681 mg) was dissolved in n-propanol (60 mL), 6-chloropurine nucleoside (300 mg) and triethylamine (4.5 mL) were added and heated to 70 ° C for 8 h; The solvent was recovered by liquid chromatography on silica gel eluting with chloroform-methanol (20:1) to give a white solid N 6 -(4-phenylpiperazinyl)-adenosine (230 mg) : positive ion ESIMS «/z 413[M + H] + and 435 [M + Na] + ; Negative ion ESIMS mlz 411 [M—H]—he mouth 447 [M+Cl]— ;]H NMR (300MHz, DMSO-c3 ⁇ 4): adenosine moiety 8.43 (IH, s, H-2), 8.27 (IH, s, H-8), 5.92 (IH, d,
- 2-furaldehyde oxime (1.04g) was dissolved in EtOH (50mL), force! 10% Pd/C (200mg) and concentrated hydrochloric acid (4mL) Hydrogenation under normal pressure; removal of Pd/C by filtration, recovery of solvent from the filtrate, dissolution of ethyl acetate, filtration to give white solid 2-furanmethylamine hydrochloride ( 1.13 g) o.
- Step 3 2-furanmethylamine hydrochloride ( 281 mg) was dissolved in n-propanol (60 mL), 6-chloropurine nucleoside (200 mg) and triethylamine (3 mL) were added and heated to 70 ° C for 8 h.
- 2-thiophenecarboxaldehyde oxime (2.75 g) was dissolved in HOAc (25 mL), Zn powder (8.63 g) was added, and stirred at room temperature for 6 h; excess Zn powder and ZnOAc were removed by filtration, and the HOAc solution was evaporated to give a yellow oil.
- 2-thienylmethylamine (1.25 g)
- 3-methoxy-4-hydroxybenzylamine hydrochloride (3.31 g) was dissolved in n-propanol (70 mL), and 6-chloropurine nucleoside (1 g) and N N-di were added.
- N 6 -(3-methoxy-4-hydroxybenzyl)-2',3'-0-propionyl-adenosine 200 mg obtained in the above examples, EDCI (129.8 mg), DMAP (110.2 mg) and lauric acid (99.36 mg) - and added to dry dichloromethane (20 mL), and the reaction was stirred at room temperature for 3 h; the solvent was recovered from the reaction mixture and purified by silica gel column chromatography using chloroform-methanol (100:1) Elution gave a pale yellow solid N 6 -(3-methoxy-4-lauroyloxybenzyl)-2',3'-0-propylidene-adenosyl-5'-laurate (210 mg) : positive ion ESIMS 808 [M+H] + , 830 [M+Na] + , 546 [M+K]+.
- N 6 -(3-methoxy-4-octanoyloxybenzyl)-2',3'-0-propionyl-adenosyl-5'-octanoate is added to the aqueous formic acid solution ( 20mL, 50% V / V), the reaction was stirred for 12h at room temperature; recovery solvent by silica gel column chromatography using chloroform-methanol (50: 1 elution) to give a pale yellow solid N 6 - (3- methoxy - 4-octanoyloxybenzyl)-adenosyl-5'-octanoate (85 mg) : positive ion ESIMS w/z 656.5 [M+H] + , 678.5 [M+Na] + , 696.5 [M+K ]+.
- N 6 -(3-methoxy-4-hydroxybenzyl) -2',3'-C»-propionyl-adenosyl-5'-n-octanoate 150 mg was added to the formic acid.
- the aqueous solution (20 mL, 50% V/V) was stirred at room temperature for 12 h.
- Example 28 N 6 -(3-methoxy-4-butyryloxybenzyl)-adenosyl-5'-butyrate and N 6 -(3-methoxy-4-butanoyloxy Preparation of benzyl)-adenosine
- the reaction was stirred at room temperature for 12 h; the solvent was evaporated, and purified by silica gel column chromatography eluting with chloroform-methanol (50:1) to give N 6 -(3-methoxy-4-butanoyloxybenzyl) - adenosine-5'-butyrate (80 mg) and N 6 -(3-methoxy-4-butyryloxybenzyl)-adenosine (60 mg): ' ⁇ NMR (300 MHz, OMSO- d 6 ):
- N 6 -(3,4-methylenedioxyphenyl)-2',3'-0-propionyl-adenosyl-5'-n-propyl ether (260 mg) was added to aqueous formic acid (20 mL). , 50% V / V), the reaction was stirred at room temperature for 12 h; the solvent was recovered to give a pale yellow crude.
- the second step is to take N 6 -[l-(3,45-trimethoxyphenyl)ethyl] -2',3'- ⁇ 9-propionyl-adenosyl-5'-p-methoxyphenylpropionic acid
- the ester 160 mg was added to a formic acid aqueous solution (20 mL, 50 V/V), and the mixture was stirred at room temperature for 12h.
- a formic acid aqueous solution 20 mL, 50% V/V
- N 5 -[(S)-1-(phenyl)-propyl]-2',3'-0-propylidene-adenosine (330 mg) and p-toluene acrylate (150 mg), EDCI (297.40 mg) and DMAP (236.90 mg) were added to dry dichloromethane (15 mL), and stirred at room temperature for 4 h; distilled water (30 mL) was added to the reaction mixture and extracted with dichloromethane (3 ⁇ 30 mL); the chloroform phase was dried over anhydrous sodium sulfate, filtered, concentrated and purified by silica gel column chromatography using chloroform-methanol: ethyl (2001), to give a pale yellow solid N 6 - [(S) -1- ( phenyl) -propyl]-2',3'-0-propane-adenosyl-5'-p-toluene acrylate (235 mg).
- ⁇ 6 -[(5)-1-(phenyl)-propyl]-2',3'-0-propylidene-adenosyl-5'-p-toluene acrylate 230 mg was added to The aqueous solution of formic acid (20 mL, 50% V/V) was stirred at room temperature for 12 h.
- N 6 -[(1R)-1-(phenyl)-propyl]-2',3'- ⁇ 9-propionyl-adenosine (500.0 mg) obtained in the above examples was added to dryness.
- THF 40 mL
- NaH 500.0 mg
- N 6 -[(1R)-1-(phenyl)-propyl]-2',3'- ⁇ 9-propionyl-adenosine 500.0 mg was added to dry THF (40 ml). After being completely dissolved, NaH (500.0 mg) was slowly added at room temperature, and reacted at room temperature for 2 h; n-propyl iodide (699.1 mg) was added to dry THF (10 mL), and the reaction mixture was added dropwise with a separating funnel at room temperature.
- 1-(4-methoxyphenyl)-butanone oxime 870mg was dissolved in EtOH (50mL), 10% Pd/C (95mg) and concentrated hydrochloric acid (2.38mL), atmospheric pressure Hydrogenation; the reaction mixture was filtered to remove Pd/C, and the solvent was evaporated, and the mixture was evaporated to ethyl ether, and filtered to give a white solid, 1-(4-methoxyphenyl)-butylamine hydrochloride (965 mg).
- 1,2-diphenylethanone oxime (5.39g) is dissolved in EtOH (50mL), force! ] 10% Pd/C (541mg) and concentrated hydrochloric acid (13.47mL), hydrogenation at atmospheric pressure; the reaction solution was filtered to remove Pd/C, and the filtrate was recovered, dissolved in ethyl acetate and filtered to obtain white solid 1-(1) , 2-diphenyl)-ethylamine (5.9 g).
- diphenylmethylamine hydrochloride (583 mg) was dissolved in n-propanol (60 mL), 6-chloropurine nucleoside (200 mg) and triethylamine (9 mL) were added and heated to 70 ° C.
- 6-methoxy-1,2,3,4-tetrahydronaphthalen-1-one oxime (1.87g) was dissolved in EtOH (50mL), 10% Pd/C (150mg) and concentrated hydrochloric acid (4mL), hydrogenation at atmospheric pressure; the reaction solution was filtered to remove Pd/C, and the filtrate was recovered. The solvent was dissolved in ethyl acetate and filtered to give 6-methoxy-1,2,3,4-tetrahydronaphthalene as white solid.
- 1-amine hydrochloride (2.13 g).
- D-phenylalanine (231 mg) was dissolved in a mixed solvent of 1,4-dioxane and water (1:1, 6 mL), and 6-chloropurine nucleoside (200 mg) and K 2 C0 3 (192 mg) were added.
- D-tyrosine ethyl ester hydrochloride (686 mg) was dissolved in n-propanol (50 mL), 6-chloropurine nucleoside (200 mg) and triethylamine (3 mL) were added and heated to 80 ° C for 10 h.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012542331A JP2013513551A (ja) | 2009-12-10 | 2009-12-10 | N6−置換アデノシン誘導体とn6−置換アデニン誘導体の鎮静、催眠,抗うつ,抗痙攣,抗てんかん,抗パーキンソン病と認知証予防・治療の用途 |
EP09851974.7A EP2511283A4 (en) | 2009-12-10 | 2009-12-10 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND THEIR USE |
PCT/CN2009/075478 WO2011069294A1 (zh) | 2009-12-10 | 2009-12-10 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
US13/515,152 US10174033B2 (en) | 2009-12-10 | 2009-12-10 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof |
CN200980162826.5A CN102812033B (zh) | 2009-12-10 | 2009-12-10 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
CA2783859A CA2783859A1 (en) | 2009-12-10 | 2009-12-10 | N6-substituted adenosine derivatives and n6-substituted adenine derivatives and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2009/075478 WO2011069294A1 (zh) | 2009-12-10 | 2009-12-10 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011069294A1 true WO2011069294A1 (zh) | 2011-06-16 |
Family
ID=44145091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/075478 WO2011069294A1 (zh) | 2009-12-10 | 2009-12-10 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10174033B2 (zh) |
EP (1) | EP2511283A4 (zh) |
JP (1) | JP2013513551A (zh) |
CN (1) | CN102812033B (zh) |
CA (1) | CA2783859A1 (zh) |
WO (1) | WO2011069294A1 (zh) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
US8940752B2 (en) | 2009-06-29 | 2015-01-27 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
US9199982B2 (en) | 2011-09-02 | 2015-12-01 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US9309251B2 (en) | 2012-04-02 | 2016-04-12 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
US9403847B2 (en) | 2009-12-18 | 2016-08-02 | Incyte Holdings Corporation | Substituted heteroaryl fused derivatives as P13K inhibitors |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
TWI650328B (zh) * | 2014-11-11 | 2019-02-11 | 中央研究院 | 用於預防及治療神經退化疾病及疼痛之化合物 |
US10301348B2 (en) | 2013-10-23 | 2019-05-28 | Academia Sinica | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
US10336759B2 (en) | 2015-02-27 | 2019-07-02 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
TWI668007B (zh) * | 2014-11-11 | 2019-08-11 | 中央研究院 | 用於預防及治療神經退化疾病及疼痛之化合物 |
US10851109B2 (en) | 2014-02-11 | 2020-12-01 | Mitokinin Llc | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
US11414419B2 (en) | 2017-06-21 | 2022-08-16 | Mitokinin, Inc. | Substituted purines for the treatment of neurodegenerative and mitochondrial diseases |
CN117338801A (zh) * | 2023-11-13 | 2024-01-05 | 河北医科大学 | N6-取代腺苷衍生物或n6-取代嘌呤衍生物在制备减轻围术期神经炎症药品中的应用 |
CN117338801B (zh) * | 2023-11-13 | 2024-06-21 | 河北医科大学 | N6-取代腺苷衍生物或n6-取代嘌呤衍生物在制备减轻围术期神经炎症药品中的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
CN104173363B (zh) * | 2013-05-28 | 2019-12-13 | 中国医学科学院药物研究所 | 一种腺苷化合物在制备防治应激障碍药物中的用途 |
US20160024135A1 (en) * | 2014-07-27 | 2016-01-28 | Zhejiang Subtropical Crops Research Institute | Adenosine receptor activation reagent and the uses of thereof |
CZ308881B6 (cs) * | 2014-12-09 | 2021-08-04 | Univerzita Palackého v Olomouci | 6-aryl-9-glykosylpuriny a jejich použití |
JP7136786B2 (ja) * | 2017-01-27 | 2022-09-13 | アカデミア シニカ | 痛みの予防および治療に使用するための鎮痛効果を有する化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002018404A2 (en) * | 2000-08-30 | 2002-03-07 | F. Hoffmann-La Roche Ag | Nucleoside derivatives for the treatment of hepatitis c |
WO2004058791A2 (en) | 2002-12-30 | 2004-07-15 | Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
CN1217952C (zh) * | 1997-11-08 | 2005-09-07 | 葛兰素集团有限公司 | 化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL128629C (zh) * | 1966-05-07 | |||
NL130136C (zh) * | 1966-10-20 | |||
DE1962387C2 (de) * | 1969-12-12 | 1983-08-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | N↑6↑-(3-Chlorbuten(2)-yl)-adenosin |
US4593019A (en) * | 1984-10-26 | 1986-06-03 | Warner-Lambert Company | N6 -tricyclic adenosines |
US20050165029A1 (en) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
BRPI0508488A (pt) * | 2004-03-05 | 2007-07-31 | Cambridge Biotechnology Ltd | compostos terapêuticos |
ES2645043T3 (es) | 2009-11-13 | 2017-12-01 | Academia Sinica | Compuestos de doble acción que se dirigen al receptor A2A de adenosina y al transportador de adenosina para la prevención y el tratamiento de enfermedades neurodegenerativas |
-
2009
- 2009-12-10 JP JP2012542331A patent/JP2013513551A/ja active Pending
- 2009-12-10 CA CA2783859A patent/CA2783859A1/en not_active Abandoned
- 2009-12-10 WO PCT/CN2009/075478 patent/WO2011069294A1/zh active Application Filing
- 2009-12-10 CN CN200980162826.5A patent/CN102812033B/zh active Active
- 2009-12-10 US US13/515,152 patent/US10174033B2/en not_active Expired - Fee Related
- 2009-12-10 EP EP09851974.7A patent/EP2511283A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217952C (zh) * | 1997-11-08 | 2005-09-07 | 葛兰素集团有限公司 | 化合物 |
WO2002018404A2 (en) * | 2000-08-30 | 2002-03-07 | F. Hoffmann-La Roche Ag | Nucleoside derivatives for the treatment of hepatitis c |
WO2004058791A2 (en) | 2002-12-30 | 2004-07-15 | Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
Non-Patent Citations (6)
Title |
---|
KAREL DOLEZAL; IGOR POPA; EVA HAUSEROVA; LUKAS SPICHAL; KUHELI CHAKRABARTY; ONDREJ NOVAK; VLADIMIR KRYSTOF; JIRI VOLLER; JAN HOLUB: "Preparation, biological activity and endogenous occurrence of N 6-benzyladenosines", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, 2007, pages 3737 - 3747 |
LAKSHMIP.KOTRA; KONSTANTINEK.MANOUILOV, JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 5202 |
LAMONTAGNE; MAURICE P., JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 20, 1983, pages 295 |
MADAN M. KWATRA; EDWARD LEUNG; M. MARLENE HOSEY; RICHARD D. DREEN, N 6-PHENYLADENOSINES: PRONOUNCED EFFECT OF PHENYL SUBSTITUENTS ON AFFINITY FOR A2 ADENOSINE RECEPTORS, vol. 30, 1987, pages 954 - 956 |
NAI-KUEI HUANG; YIJUANG CHERN; JIM-MIN FANG; CHIA-I LIN; WANG-PING CHEN; YUN-LIAN LIN: "Neuroprotective Principles from Gastrodia elata", J. NAT. PROD., vol. 70, 2007, pages 571 - 574 |
See also references of EP2511283A4 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940752B2 (en) | 2009-06-29 | 2015-01-27 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
US10428087B2 (en) | 2009-06-29 | 2019-10-01 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
US10829502B2 (en) | 2009-06-29 | 2020-11-10 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
US11401280B2 (en) | 2009-06-29 | 2022-08-02 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
US9975907B2 (en) | 2009-06-29 | 2018-05-22 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
US9434746B2 (en) | 2009-06-29 | 2016-09-06 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
US9403847B2 (en) | 2009-12-18 | 2016-08-02 | Incyte Holdings Corporation | Substituted heteroaryl fused derivatives as P13K inhibitors |
US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
US9815839B2 (en) | 2010-12-20 | 2017-11-14 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9527848B2 (en) | 2010-12-20 | 2016-12-27 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
US11433071B2 (en) | 2011-09-02 | 2022-09-06 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
US10376513B2 (en) | 2011-09-02 | 2019-08-13 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US9707233B2 (en) | 2011-09-02 | 2017-07-18 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US9730939B2 (en) | 2011-09-02 | 2017-08-15 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US11819505B2 (en) | 2011-09-02 | 2023-11-21 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
US10092570B2 (en) | 2011-09-02 | 2018-10-09 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US10646492B2 (en) | 2011-09-02 | 2020-05-12 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
US9199982B2 (en) | 2011-09-02 | 2015-12-01 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
US9309251B2 (en) | 2012-04-02 | 2016-04-12 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
US9944646B2 (en) | 2012-04-02 | 2018-04-17 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
US10259818B2 (en) | 2012-04-02 | 2019-04-16 | Incyte Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
EP2953950A4 (en) * | 2013-02-11 | 2016-10-12 | Univ California | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES |
US10723737B2 (en) | 2013-02-11 | 2020-07-28 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
US11427588B2 (en) | 2013-02-11 | 2022-08-30 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |
US10301348B2 (en) | 2013-10-23 | 2019-05-28 | Academia Sinica | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
US10851109B2 (en) | 2014-02-11 | 2020-12-01 | Mitokinin Llc | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
US10479803B2 (en) | 2014-06-11 | 2019-11-19 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US11999751B2 (en) | 2014-06-11 | 2024-06-04 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
US11130767B2 (en) | 2014-06-11 | 2021-09-28 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
TWI650328B (zh) * | 2014-11-11 | 2019-02-11 | 中央研究院 | 用於預防及治療神經退化疾病及疼痛之化合物 |
TWI668007B (zh) * | 2014-11-11 | 2019-08-11 | 中央研究院 | 用於預防及治療神經退化疾病及疼痛之化合物 |
US11084822B2 (en) | 2015-02-27 | 2021-08-10 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
US10336759B2 (en) | 2015-02-27 | 2019-07-02 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US10125150B2 (en) | 2015-05-11 | 2018-11-13 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US11414419B2 (en) | 2017-06-21 | 2022-08-16 | Mitokinin, Inc. | Substituted purines for the treatment of neurodegenerative and mitochondrial diseases |
CN117338801A (zh) * | 2023-11-13 | 2024-01-05 | 河北医科大学 | N6-取代腺苷衍生物或n6-取代嘌呤衍生物在制备减轻围术期神经炎症药品中的应用 |
CN117338801B (zh) * | 2023-11-13 | 2024-06-21 | 河北医科大学 | N6-取代腺苷衍生物或n6-取代嘌呤衍生物在制备减轻围术期神经炎症药品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US10174033B2 (en) | 2019-01-08 |
EP2511283A1 (en) | 2012-10-17 |
CN102812033B (zh) | 2015-11-25 |
JP2013513551A (ja) | 2013-04-22 |
CN102812033A (zh) | 2012-12-05 |
CA2783859A1 (en) | 2011-06-16 |
EP2511283A4 (en) | 2013-07-03 |
US20130045942A1 (en) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011069294A1 (zh) | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 | |
US6908924B2 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
EP3262057B1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
AU2002365234A1 (en) | N4-acylcytosine nucleosides for treatment of viral infections | |
JP2008513428A (ja) | Dna−pk阻害剤 | |
WO2014135107A1 (zh) | 新的核苷氨基磷酸酯化合物及其应用 | |
JPH0680061B2 (ja) | 新規なプリン誘導体 | |
WO2014094544A1 (zh) | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 | |
WO2007042668A1 (fr) | Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique dans le traitement d' un dysfonctionnement lie au recepteur 1 de la mch | |
US5721240A (en) | 9-substituted-8-unsubstituted-9-deazaguanines | |
JPS6157584A (ja) | 抗ウイルス化合物 | |
WO2021227440A1 (zh) | 一类芳基葡糖苷衍生物及其制备方法和应用 | |
JP2015172077A (ja) | N6−置換アデノシン誘導体とn6−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途 | |
CN104382924B (zh) | N6‑取代腺苷衍生物和n6‑取代腺嘌呤衍生物及其用途 | |
EP2167472A2 (fr) | Dérives de 1 -benzylpyrazole, leur preparation et leur application en therapeutique | |
FR2862968A1 (fr) | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique | |
WO2021227439A1 (zh) | 一种芳基葡糖苷衍生物 | |
JP2005255666A (ja) | 5−リポキシゲナーゼ阻害活性を有する6−アルキルアミノ−2,2’−二重置換−7,8−二重置換−2h−1−ベンゾピラン誘導体 | |
WO2021227441A1 (zh) | 芳基葡糖苷衍生物及其在药物中的用途 | |
NO854692L (no) | Fremgangsmaate ved fremstilling av imidazopyridazinderivater. | |
TW201026313A (en) | Bicyclic morphine-6-glucuronide derivatives, preparation and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980162826.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09851974 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2783859 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012542331 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6118/DELNP/2012 Country of ref document: IN Ref document number: 2009851974 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13515152 Country of ref document: US |